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Ageing involves alterations in physiological and cellular functions that may 
affect changes in a pharmacological response.  General changes that can influence the 
pharmacokinetics (PK) of a drug have been established but certain controversy 
remains with respect to ageing changes in function and expression of Phase I 
cytochrome P450 metabolic enzymes (CYP450) and drug transporters such as P-
glycoprotein (P-gp) which can influence brain permeability.  Pharmacodynamic (PD) 
responses of drugs are also known to be altered in the elderly but the mechanisms 
involved are not well-elucidated.  It is also unclear if cholinergic hypofunction which 
occurs on ageing may exert any influence on the PD response of a cholinergic-
interfering drug.   
This project explored PK/PD changes in old and young Lister hooded (LH) 
rats utilizing the gold standard Alzheimer’s disease (AD) drugs, Aricept, Tacrine, 
Galantamine and Memantine.  These drugs were chosen for their varying PK profiles 
and various modes of action in AD treatment which include cholinergic stimulation.  
The use of the LH rat strain also enabled us to explore if there was an over-reliance on 
the primary rat model extensively used in ageing research, the Fischer 344 (F344) rat.  
It was found that the gold standard AD drugs underwent similar PK changes 
due to age in the LH rats compared to humans.  This was despite certain species 
distinctions that may exist in terms of CYP metabolism, urinary excretion and P-gp 
function.  Similar variations in body fat and water with age may have had a greater 
impact in predicting PK parameter alterations seen in ageing humans.  Enhanced PD 
sensitivity was observed in the aged rat which was attributed not only to PK but to 
modifications in expression of receptors that participated in the PD response.  The M2 
muscarinic acetylcholine receptor in particular was postulated to play a key role in 
 vi 
determining cholinergic behavioural alterations seen in the aged LH rat on Tacrine 
dosing.  Other mechanisms may also be involved although the detailed signalling 
pathway remains to be elucidated.  These most likely involve homeostatic 
mechanisms which are known to be challenged in the elderly. 
On comparison of obtained results to current knowledge from studies in aged 
F344 rats, the LH rat was found to undergo less severe PK and PD responses.  Other 
studies have also noted the trend of an accelerated ageing seen in F344 rats.  This, in 
addition to the higher prevalence of chronic progressive nephropathy seen in F344 
rats, stresses the need for the study of several rat strains in the determination of ageing 
trends before translation into humans. 
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Declining birth rates, improved living standards, and increasingly advanced 
healthcare have resulted in a rapidly ageing population deemed globally pervasive and 
largely irreversible (UN World Population Ageing report: 1950-2050).  Singapore has 
one of the fastest ageing populations in the world with a geriatric (> 65 years of age) 
population of 7.2% (in year 2000) projected to jump to 18.4% by year 2030 (Mamun et 
al., 2004).  Population ageing brings with it major shifts in economics, social policies and 
lifestyles but the most pressing burden it places would irrevocably be on healthcare.  The 
elderly are subject to an increased vulnerability to disease, making them the consumers of 
a disproportionately larger share of medicines and healthcare services than any other age 
group.  Problems which plague geriatric healthcare are numerous and complex.  Along 
with polypharmacy
1
, inappropriate prescribing of medications, poor compliance, and 
multimorbidity
2
, ageing is also known to effect changes in pharmacological response due 
to an altered physiology of organ and cellular function (Mamun et al., 2004, McLean and 
Le Couteur, 2004, Hilmer, 2008, Laroche et al., 2009).  These factors eventually 
culminate in the increased incidence of adverse drug reactions (ADRs) (Moore et al., 
2007) and a potentially poorer pharmacological efficacy in the elderly compared to their 
younger counterparts. 
A pharmacological response comprises of two branches of science: 
Pharmacokinetics (PK), the study of how a drug is absorbed, distributed, metabolised and 
excreted by the body; and pharmacodynamics (PD), the study of the response a drug 
elicits from the body mediated by its binding to target receptors or molecules, signal 
                                                 
1 The use of multiple medications by a patient. 
2 The co-existence of two or more chronic conditions in an individual, also termed comorbidity. 
 2 
transduction pathways and regulation by homeostatic processes (Turnheim, 2004).  These 
two sciences are often studied together to establish a PK/PD effect of a drug since a PD 
response varies correspondingly with the level of drug in the body.   
Table 1 details the various changes that occur on ageing in humans which can 
affect the PK of a drug.  An established decline in glomerular filtration rate (GFR) seen 
in the elderly has an influential effect on PK as most drugs and their metabolites undergo 
renal excretion (Muhlberg and Platt, 1999).  Clinically, this necessitates a modification of 
drug dosage levels and is aided by the Cockcroft-Gault equation which estimates the 
GFR by taking into account age, gender and creatinine serum concentration.  Ageing also 
accompanies a decline in liver size and blood flow, but not all drugs undergo a reduced 
hepatic metabolism (McLean and Le Couteur, 2004).  Certain drugs depend on the 
activity of intrinsic liver enzymes for clearance or alternatively, the extent of plasma 
protein binding which dictates the amount of free drug taken up allowing access to these 
enzymes (low extraction drugs).  This is opposed to drugs whose metabolic clearance 
depends on the rate of liver blood flow (high extraction drugs) since they associate well 
with liver enzymes.  The influence of age on intrinsic liver enzymes such as the Phase I 
cytochrome P450 (CYP450) enzymes in humans is controversial and largely unclear.  
Phase II enzymes which mediate conjugation reactions (glucoronidation, sulfation, 
acetylation and glycation) in contrast, have reported little change on ageing (Mc Lean and 
Le Couteur, 2004).  Additionally, plasma protein levels vary on ageing, impacting free 
fractions of drug available for uptake.  The volume of distribution of drugs based on their 
lipophilicity can also be altered in the elderly as body fat increases while muscle mass 
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(body water) declines on ageing.  This affects the level of drug circulating in the blood 
which may influence pharmacological response. 
Few studies have looked at transporter expression and activity changes with age 
in PK relevant organs.  This is surprising considering membrane transporters significantly 
affect the uptake of drugs into relevant organs, limiting absorption, tissue distribution, 
elimination as well as drug target accessibility.  P-glycoprotein (P-gp), an efflux pump 
with wide substrate specificity, is expressed in excretory organs and tissue membrane 
barriers.  It affects drug absorption from intestines, excretion into biliary canaliculi and 
renal tubules, and most significantly, drug entry into tissues, particularly the brain.  Its 
importance in PK has led to the incorporation of P-gp transport assays into preclinical 
drug discovery screening, supported by mdr (multi-drug resistant gene, syn. ABCB1) 
knock out mice and in vitro cell systems (Lin and Yamazaki, 2003).  Most ageing studies 
have focussed on P-gp expression and activity in lymphocytes, largely neglecting other 
organs relevant to PK (Mangoni et al., 2007).  Results have also been controversial with 
some reporting an increase while others reporting a decrease or no change in P-gp 
expression and activity, preventing any distinct conclusions to be drawn.  Recently 
however, a study found a downregulation of P-gp activity in the blood brain barrier 
(BBB) of elderly subjects, allowing greater brain penetration of P-gp substrate verapamil 
(Bartels, 2008, Toornliviet, 2006).  Ageing could therefore have a significant impact on 
CNS sensitivity to drugs with P-gp substrate specificity.   
PD changes with age are less clearly elucidated compared to PK.  Valid studies to 
demonstrate PD changes should measure drug concentrations in blood/plasma to ensure 
that sensitivity alterations are not due to PK.  Although the elderly are generally more 
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sensitive to pharmacotherapy, this is not universal, as seen from Table 2 (left panel) 
which reveals bidirectional PD alterations of a range of drugs upon ageing.  The CNS in 
particular is especially vulnerable on ageing with brain weight decreasing by 20%, 
progressive grey matter loss with maintenance of white matter, and an overall drop in 
synapse number (Turnheim, 2004).  Centrally acting drugs consistently shown to produce 
sensitized reactions in the elderly apparently independent of PK changes include 
benzodiazepines (e.g. midazolam), opioids (e.g. morphine) and anticholinergic tricyclic 
antidepressants (e.g. imipramine, amytriptiline) (Albrecht et al., 1999, Villesen et al., 
2007, Lotrich and Pollock, 2005).  This translates to a greater incidence of falls and hip 
fractures, increased and prolonged pain relief, enhanced anticholinergic side effects and 
potential adverse cardiac events such as QT prolongation which can prove fatal in the 
elderly.  Mechanisms by which these PD alterations occur are still relatively unknown but 
are usually attributed to altered neurotransmitter and receptor levels (see Table 2, right 
panel).  Other factors proposed to contribute to this include molecular alteration of the G-
protein coupling/uncoupling-signalling activities, modified intracellular calcium kinetics, 
sex and growth hormone changes, and a decline in glucose and oxygen availability 
(Alemany et al., 2006, ElDesoky 2007, El Beheiry et al., 2007, Bowie and Slattum, 
2007). 
Studying and establishing trends in the aged pharmacological response is fraught 
with various roadblocks.  A key challenge lies in the great heterogeneity of the elderly 
population where the state of health varies substantially from the very fit elder person 
who experiences little or no health problems to the frailest of the elderly, who are usually 
encumbered with multimorbidities, general weakness, distinct weight loss and an 
 5 
increased susceptibility to adverse outcomes.  Other confounders that limit the accurate 
study of the aged pharmacological response include gender (as a higher proportion of 
women reach old age than men), pharmacogenetics, and environmental factors such as 
smoking, diet, and co-administered drugs.   
Clinical trials that could potentially evaluate ageing changes in pharmacological 
response often lack appropriate representation of the elderly subgroup (Levy et al., 2006, 
Inderjeeth et al., 2009).  This is especially ironic when the drug is expected to be 
extensively used in the elderly population (Lewis et al., 2003).  Exclusion criteria based 
on the presence of comorbidities resulting in organ function abnormalities or concurrent 
drug intake usually account for this under-representation.  Other factors such as limited 
access to clinical trials due to transport and communicative difficulties or poor protocol 
adherence have also been suggested to play a role (Levy, 2006).  For drugs with a narrow 
therapeutic index, the dose range derived from such clinical trials could have severe 
implications in the elderly population.   This was best demonstrated in the case of 
warfarin, where despite having similar PK, the elderly proved more sensitive to its 
anticoagulant effect compared to the young (Hammerlein et al., 1998).  Prior clinical 
trials to establish warfarin induction regimens recruited patients with a mean age of 52 
years, and the loading dose of 10 mg recommended from the trial resulted in over-
anticoagulation, poor maintenance of therapeutic drug levels in the elderly (Gedge et al., 
2000) and significant increase in risk of major haemorrhage (Jacobs, 2008).  Since then, 
newly adjusted dosage regimens have been recommended from trials with a focus on 
elderly patients (Siguret et al., 2005 [mean age 84.6 years], Gedge et al., 2000 [mean age, 
stratified into two groups – 70 and 80 years]).  A comprehensive investigation of drug 
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disposition and response in the elderly is imperative in drug development and apart from 
efforts to include more elderly in clinical trials which is currently being enforced (US 
GAO Report, 2007); a greater understanding of the aged pharmacological response can 
also be achieved preclinically in animal models.  
The use of animals in ageing research has greatly contributed to the depth of 
knowledge uncovered in ageing mechanisms and age-associated diseases.  The National 
Institute of Ageing, formed in 1974 under the US National Institutes of Health, created 
the first central colony of ageing rodents, enforcing the use of two inbred rat genotypes, 
the Fischer 344 (F344) and the Brown Norway (BN) rat, and a hybrid strain, F344BN, 
along with several strains of mice and even caloric-restricted rodents in ageing research 
work (www.nia.nih.gov).  The accessibility to these aged strains has encouraged their 
heavy usage in ageing research, particularly so for the F344 rat, which was used in 54% 
of reports using rats in the Journal of Gerontology from 1985-90 (Weindruch and 
Masoro, 1991).  Rodents closely resemble humans in terms of physiological and cellular 
characteristics as well as anatomical function and architecture.  Similarly, their functional 
decline on ageing generally mimics that of humans, though certain distinctions exist.  For 
example, rats generally undergo few ageing changes in the kidney with no change in 
GFR, with the exception of albino strains (Sprague Dawley, Fischer 344) which 
experience chronic progressive nephropathy (CPN).  This involves proteinuria and 
glomerular alterations that may lead to a decline in GFR but is more dependent on strain 
and sex rather than age (McLean and Le Couteur, 2004, Baylis and Corman, 1998, 
Goldstein et al., 1988).  Changes in plasma protein expression and body fat content in 
aged rats however, were found to parallel that of humans (Delp et al., 1998, Satterwhite 
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and Boudinot, 1990).  In addition, decreased neuronal and synaptic densities along with 
other central deficits which accompany cognitive decline have been established in rodent 
models (Terry and Buccafasco, 2003).  In contrast, while an age-related downregulation 
of CYP450 enzyme activity has been consistent in rodent models, studies in humans have 
detected no or less pronounced an effect (Schwartz, 2007).   
Limited information on PK/PD studies (i.e. studies relating PK profile to PD 
effect) using aged rodent models is available but most reported have focussed on 
anaesthetics and analgesics.  Good correlations to the aged human pharmacological 
response have been found for morphine (Jourdan et al., 2002) and midazolam (Hovinga 
et al, 1992) however no change in electroencephalogram activity towards anaesthetic 
thiopental was seen in young and old F344 rats despite an increased sensitivity found in 
the elderly (Harashima et al., 1997).  This was postulated to be due to maintenance of 
cardiac performance in aged rats whereby a decline is generally seen with age in humans.  
The translation of the aged rodent model into humans is therefore dependent on the drug 
being studied and the species-specific molecular mechanisms involved in its mode of 
action.  Nevertheless, rodents provide a practical avenue to understanding 
pharmacological response variations due to age, isolated from confounding factors 
present in a human response.  
Alzheimer’s disease (AD) is a debilitating form of dementia that commonly 
affects the elderly.  It is associated with a decline in cognitive function which manifests 
in memory loss, aphasia, confusion and mood swings, eventually leading to a loss in 
bodily functions and death.  A distinct loss in cholinergic function is reported to occur in 
AD and to a lesser extent in normal ageing.  This is depicted by decreased muscarinic and 
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nicotinic receptor expression, acetylcholine (ACh) release, choline acetyltransferase 
(ChAT) activity, and acetylcholinesterase (AChE) level detectable in both animals and 
humans (Picciotto and Zoli, 2002, Ginsberg et al., 2005, Schliebs and Arendt, 2006).  
This deficiency is said to contribute to the progressive memory loss observed on ageing 
and in AD (Terry and Buccafusco, 2003).  There are currently no drug treatments which 
stop or reverse the progression of AD but several treatments are available to alleviate the 
symptoms.  These treatments shall be referred to as ‘gold standard’ treatments as they are 
the only available drugs in the market used against AD and are referred to as such by the 
pharmaceutical industry as a standard for comparison with novel drug candidates 
(Chapman et al., 2007, Chrisholm-Burns et al., 2007).  Most of them take the form of 
cholinesterase (ChE) inhibitors (e.g. Aricept, Tacrine and Galantamine).  These serve to 
prevent the breakdown of neurotransmitter ACh, increasing its levels in the brain which 
aid in enhancing cognitive function.  Galantamine has an additional function as an 
allosteric modulator of nicotinic ACh receptors, augmenting its ChE inhibitory effect by 
increasing receptor sensitivity (Farlow et al., 2003).  Another treatment in the form of 
Memantine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, 
relieves the excitotoxicity of neurons derived from overstimulation of NMDA receptors 
by the neurotransmitter, glutamate.  Memantine provides moderately efficacious 
treatment of moderate to severe AD (Johnson and Kotermanski, 2006).   
This project investigates the effects of age on the PK and PD of gold standard AD 
drugs, Aricept, Tacrine, Galantamine and Memantine, using the aged Lister-hooded (LH) 
rat model.  These drugs were chosen for their varied PK profiles and centrally-acting 
mechanisms enabling an evaluation of physiological changes affecting PK and CNS 
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sensitivity to pharmacological agents on ageing.  Their cholinergic mechanism of action 
would also allow us to determine the extent to which the cholinergic deficiency seen with 
age may affect the magnitude of PD drug response. Table 3 illustrates the PK parameters 
of these drugs and current knowledge on disposition changes with age in humans and 
rats.  Only Aricept and Galantamine were found to have altered PK profiles in the elderly 
while no PK data is currently available in aged animals for the gold standard AD drugs.  
A study by Kosasa et al. (1999) found higher Aricept and Tacrine levels in blood and 
brain of aged F344 rats at a single time-point which was concluded to be responsible for 
the enhanced PD response (ChE inhibition) seen.  PD changes with age for Galantamine 
were demonstrated in a recent publication which revealed a significantly greater learning 
improvement in young (4 months) rabbits versus old (27 months) rabbits although no 
supporting PK data was provided (Li et al., 2008).  No PD changes upon ageing were 
reported for Memantine but NMDA receptor expression was found to be decreased in the 
aged rat brain (Mitchell and Anderson, 1998, Liu et al., 2008). 
This project was carried out in the LH rat to explore differences in strain selection 
with respect to ageing research.  The LH rat model is a black-hooded outbred rat with 
superior eyesight compared with albino strains.  This trait, along with their high 
inquisitiveness and ease in training makes them common subjects for cognitive 
behavioural studies.   As mentioned before, the F344 rat is heavily used in ageing 
research and a possible over-reliance on a single strain that arises from this could have 
negative implications when generalizing results across other ageing organisms.  
Understanding the aged pharmacological response in other strains of rat such as the LH 
rat would therefore define any crucial differences and assure that ageing changes are 
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being appropriately characterized.  The translational potential of aged animal models in 
the prediction human responses can also be assessed in this study.  Through the carrying 
out of PK profiles in old LH rats, potential issues arising from the use of old animals in 
experimental procedures such as cannulation surgery and profile blood sampling can be 
considered to examine the applicability of their use in the normal PK screening cascade.  
In addition, as normal ageing and age-associated neurodegenerative diseases such as AD 
share similar processes (e.g. cholinergic degeneration), the study of AD gold standard 
drugs on a normal ageing phenotype would serve to correlate with the application of 
these drugs in a disease setting, thereby examining potential changes in efficacy of 





Observed change with age Reason for change Effect on pharmacokinetics References 
Absorption 
Slowed gastric motility Enteric neurodegeneration 
Overall minimal effect on PK 
although pH change may affect 
dissolution of certain drugs. 
Gidal, 2006, Camilleri et al., 2008 
Gastric pH change Not direct effect of ageing but likely due 
to Helicobacter pylori infection and 
proton pump inhibitor usage common in 
elderly 
Feldman 1997, Hurwitz 1997, 
McLean and Le Couteur, 2004 
Changes in intestinal wall absorption Transporter expression/activity changes, 
decrease in surface area and intestinal 
blood flow  
McLean and Le Couteur, 2004 
Distribution 
Increase in body fat and decrease in body 
water 
Lean muscle mass loss results in water 
loss.  Cause of fat gain unclear. 
Plasma levels of drug may be 
affected as well as time to 
distribute into and out of tissues 
and target organ accessibility.  
Beaufrere and Morio, 2000 
Low body weight in frail elderly Multimorbidities Turnheim, 2004 
Membrane permeability changes Transporter expression  
e.g. P-gylcoprotein decreased activity in 
blood-brain barrier 
Toornvliet 2006, Bartels 2008 
Warrington et al., 2004,  
Mangoni, 2007 
Plasma protein expression changes affecting 
free drug concentration 
More due to pathophysiological states 
than age e.g. post-operative or 
malnourished state 
McLean and Le Couteur, 2004 
Cusack, 2004, Grandison and 
Boudinot, 2000 
Metabolism 
Liver volume and blood flow decline Unknown 
Decreased clearance and 
increased exposure of high 
extraction drugs with variable 
effect on low extraction drugs. 
Pang and Rowland, 1977, Le Couteur 
and McLean, 1998, Butler and Begg, 
2008 
Conflicting changes reported in 
expression/activity of Phase I CYP enzymes 
with little change in Phase II enzymes 
Possibly hormone-regulated Le Couteur and McLean, 1998 and 
2004, Wauthier et al., 2007, 
Schmucker, 2004, Cusack, 2004,  
Excretion 
Decrease in glomerular filtration rate Reduction in organ volume and blood 
flow, arteriosclerosis, increased number 
of sclerotic glomeruli and interstitial 
fibrosis  
Decreased clearance and 
increased exposure of drugs that 
rely on renal excretion as main 
mode of elimination. 
McLean and Le Couteur, 2004, 
Muhlberg and Platt, 1999, Shi et al., 
2008, Fliser, 2008  
Changes in tubular drug transport  Unclear, possible change in transporter 
expression or due to loss of mass 
Cusack, 2004 
 





Drug  Pharmacodynamic effect  Age-related change  Effector Change 
Adenosine Heart-rate response ↔  Central nervous system 
Diazepam Sedation, postural sway ↑  Dopaminergic D1, D2  ↓ 
Diltiazem  
Acute and chronic 
antihypertensive effect 
↑  Serotonergic 5HT1A, 5HT2A  ↓ 
Acute PR interval prolongation ↓  Muscarinic cholinergic M1  ↓ 
Diphenhydramine  Postural sway ↔  Acetylcholinesterase  ↓ 
Enalapril ACE inhibition ↔  β-Adrenergic  ↓ 
Furosemide Peak diuretic response ↓  α-Adrenergic  ↔ 
Heparin Anticoagulant effect ↔  GABAergic  ? 
Isoproterenol Chronotropic effect ↓  Enkephalin/endorphin  ? 
Morphine 
Analgesic effect ↑  Autonomic nervous system 
Respiratory depression ↔  β1,β2-Adrenergic  ↓ 
Phenylephrine  α1-adrenergic responsiveness ↔  α1-Adrenergic  ↔ ↓ 
Propranolol Antagonism of chronotropic 
effects of isoproterenol 
↓  Dopaminergic  ↓ 
Scopolamine Cognitive function ↓  Parasympathetic responses  ↓ 
Temazepam Postural sway ↑  Baroreflex function  ↓ ↓ 
Verapamil Acute antihypertensive effect ↑    
Warfarin Anticoagulant effect ↑    
 (Mangoni and Jackson, 2003) (Schwartz and Abernethy, 2009) 
 
Table 2. Changes in pharmacodynamic response with age 
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2 Objectives and Approach 
 
This study seeks to investigate the PK and PD difference between aged (30 
months) and young (7 months) LH rats utilizing gold Standard AD drugs Aricept, 
Tacrine, Galantamine and Memantine.  Serial blood sampling to obtain intravenous (IV) 
and oral (PO) PK profiles will be performed to assess PK parameters while timed 
terminal brain and blood collection following oral dosing should allow measurement of 
brain penetrance. 
The underlying mechanisms by which PK may be affected with age will also be 
studied.  This may involve plasma protein binding evaluation assays, CYP450 enzyme 
activity assays with isolated liver microsomes, timed urine and stool collection to assess 
kidney and biliary function respectively, and P-gp transporter mRNA expression assays 
in various PK relevant tissues.  PD responses may also be assessed via receptor 
radiobinding assays and western immunoblotting which will evaluate changes in receptor 
binding affinity and expression on ageing.  Functional PD responsiveness will be 
analysed by measuring AChE and butyrylcholinesterase (BChE) inhibition in isolated 
aged plasma and brain tissue from rats dosed with ChEIs and also by observing intensity 
of cholinergic effects such as tremor, salivation, lacrimation and drop in rectal 
temperature upon Tacrine dosing.   
Summary of objectives 
 Determine if ageing has significant effect on PK/PD of gold Standard AD drugs 
Aricept, Tacrine, Galantamine and Memantine in the LH rat 
 Establish a clearer knowledge of PK and PD changes with ageing in the LH rat 
 Assess LH rats as a model of ageing 
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3 Materials and Methods 
3. 1 Animal maintenance 
Young (7 months, 350-450g) and old (30 months, 350-500g) male LH rats were 
used (Harlan, UK).  They were approximately 3 months old on arrival and raised in 
similar housing conditions from arrival to time of use.  Animals were kept in a specified 
pathogen-free (SPF) facility and housed in groups of three to six in individual-ventilated 
cages at a controlled temperature (20 ± 1°C) and humidity (40 ± 2%).  Rooms were on a 
twelve hour light/dark cycle (lights on 7:30am), and animals were allowed ad libitum 
access to water and food (Teklad Irradiated Global 14% Protein Maintenance Diet, 2914).  
Old animals which developed tumours or signs of disease were not utilized in the project. 
Chronically cannulated rodents are often used in PK studies as serial blood 
samples can be collected from unanaesthetized animals with minimal stress and have 
attained similar results to terminal sampling (Bardelmeijer et al., 2002).  Animals 
cannulated for PK studies were fitted with elastic harnesses and their indwelling cannulas 
were threaded through an attached hollow spring tether which was held over the cage 
with a swivel mount counter weight balanced system (Instech Solomon, PA, USA), 
thereby allowing free movement.  They were housed individually in clear cages with 
sterile bedding post-surgery and monitored daily for weight changes.  Their cannulas 
were flushed with 100 U/L heparinised saline (made with heparin sodium salt from 
Sigma Aldrich, St Louis, MO, USA) everyday to prevent clotting.  All experiments were 
carried out in accordance with the Institutional Animal Care and Use Committee 
(protocol no.: 080342) and Singapore National Advisory Committee for Laboratory 
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Animal Research (NACLAR) guidelines for the use and care of animals for scientific 
purposes and GlaxoSmithKline animal research ethical standards. 
3. 2 Drugs, chemicals and solvents 
Aricept, Galantamine and Memantine were obtained from Manus Aktteva 
(Gujarat, India).  Tacrine was purchased from Sigma Aldrich.  All drugs were in solid 
hydrochloride or hydrobromide salt form prior to dissolvation (Table 3).  Biliary excreted 
drug, Rosuvastatin (in calcium salt form), was kindly provided by Dr Edmund Chen, 
Pharmacogenetics lab in NUS.  CYP activity probe drugs Verapamil, Dextromethorphan, 
7-ethoxycoumarin, and Testosterone were obtained from Sigma Aldrich.  GSK334429B 
was used as an internal standard (I.S.) in LCMS analysis and was synthesized by 
GlaxoSmithKline (Harlow, UK).   Solvents acetonitrile, methanol, ethanol and 
ammonium acetate were obtained from Merck (Darmstadt, Germany).   
3. 3 Pharmacokinetic-based Assays 
3. 3. 1 Intravenous (IV)  and oral (PO)  PK profiling procedure 
Animals were dosed subcutaneously with analgesic (Torbugesic®, 10 mg/kg, 0.1 
ml/100g body weight (bw)) and antibiotic (Baytril®, 1 mg/kg, 0.05 ml/100g bw) 
respectively prior to surgery.  Hand-made jugular and femoral cannulas (PE50 and PE10 
polyethylene tubing, Biomed Diagnostics, USA) were surgically implanted under inhaled 
isofluorane anaesthesia and animals were given a day to recover before PK profiling 
studies.  For IV studies, 1 h infusion of post-filtered solutions of the respective drugs in 
2% DMSO (Sigma) in hydroxybetacyclodextrin (Acros Organics, Geel, Belgium) (10% 
w/v in 0.9% saline) at a 1 mg/kg dose level and 10 ml/kg/h dose volume and rate was 
performed through the femoral cannula with use of a syringe pump.  A predose blood 
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sample was taken via the jugular cannula followed by sampling at 15, 30, 45, 60, 65, 75, 
90, 120, 150, 180, 240, 300 and 360 min time-points.  To assess bioavailability, rats were 
put through a 1 day wash-out period before PO profiles were carried out with the same rat 
being given the drug they were dosed with IV before.  Rats were dosed by oral gavage at 
3 mg/kg and 5 ml/kg with drugs suspended in 1% methyl cellulose (Sigma).  Blood 
samples were collected at predose and 30, 60, 90, 120, 180, 240, 300 and 360 min.  All 
blood aliquots (duplicate tubes of 50 µl each) were added to an equal volume of water 
and kept at -80°C till LCMSMS analysis. 
Non-compartmental analysis of IV profiles was performed with WinNonlin® 
software (Pharsight, Lexington, KY, USA).  For oral profiles, linear AUC was calculated 
with Microsoft Excel and bioavailability (F) was calculated with the following formula:  
F (%) = (AUCoral /dose oral) × (dose iv/AUCiv) × 100 
3. 3. 2 Terminal collection of brain, blood and plasma samples to measure brain 
permeability and extent of cholinesterase (ChE) inhibition 
Young and old rats were dosed orally with the gold standard AD drugs at 3 
mg/kg, 5 ml/kg in 1% methyl cellulose (n=3).  A vehicle group was included as a control 
for measurement of ChE inhibition (see 3.4.1).  The rats were decapitated after 1 h and 
trunk blood collected into EDTA-coated tubes (BD Diagnostics, NJ, USA).  A portion of 
blood was aliquoted into Eppendorf tubes and centrifuged at 10, 000 rpm at 4°C to isolate 
plasma.  Whole brains were extracted and briefly rinsed with water before being 
dissected in halves and stored in tubes.  All samples were kept at -80°C till LCMSMS 
analysis. 
  18 
3. 3. 3 In vitro Brain:Blood prediction studies to evaluate plasma protein and tissue 
binding  
A 96-well equilibrium dialysis apparatus (HT Dialysis LLC, Gales Ferry, CT, 
USA) was used to determine the fraction unbound (fu) in the blood and brain for each 
drug, thereby evaluating extent of plasma protein and brain tissue binding respectively.  
The method used was adapted from Summerfield et al. (2005).  Membranes were 
conditioned in deionised distilled water (ddH2O) for 40 min and 80:20 ddH2O:ethanol the 
next 20 min, then rinsed in ddH2O before use.  Blood and brain homogenate from one 
young and one old LH rat (obtained fresh) were diluted 1:1 and 1:2 with phosphate 
buffered saline (PBS) (Sigma) respectively, then spiked with the test compound (1000 
ng/g). Aliquots of 100 µl (n = 6 replicate determinations) were loaded into half-wells of 
the 96-well equilibrium dialysis plate with PBS loaded into the opposing half-wells.  The 
plate was incubated on an orbital microplate shaker at 125 rev/min for 5 h at 37°C.  
Aliquots of blood, brain homogenate or PBS were then transferred to 1.4 ml micronic 
tubes (Micronic, Lelystad, The Netherlands) and the composition in each tube was 
balanced with control fluid, such that the volume of PBS to blood or brain was the same.  
Similar sample preparation procedure was carried out as described in 3.3.4.  The fraction 
unbound was determined as the ratio of the peak area in PBS to that in blood or brain and 
an in vitro brain:blood partition ratio can be calculated based on the equations below: 
Since Cu(blood) = Cu(brain) 
fu(blood) x  C(blood) = fu(brain) x C(brain) 
fu(blood) / fu(brain) = C(brain) / C(blood) = Kbb  
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where fu – fraction unbound; Cu – unbound drug concentration; C – total drug 
concentration; Kbb – in vitro brain:blood partition ratio 
3. 3. 4 Sample preparation and LCMSMS analysis conditions for Aricept, Tacrine, 
Memantine and Galantamine in blood and brain 
Stock solutions (100 µg/ml) of each compound were prepared in ethanol and 
standard lines ranging from 5 to 5000 ng/ml (including a 0 ng/ml blank) were done up for 
each run by serial dilution in micronic tubes.  These were spiked with blood/brain 
matrices to simulate sample conditions.  Brain samples were weighed and homogenized 
in 1 vol ddH2O with an ultrasonicating homogenizer (TOMTEC Autogiser, Receptor 
Technologies, Adderbury, Oxon, UK) while blood was diluted 1:1 with ddH2O (if not 
done already).   Aliquots of 100 and 50 µl of diluted blood and brain homogenate 
samples were prepared in micronic tubes with 50 µl ethanol added to simulate the 
standard line.  All samples and standards were then extracted by protein precipitation 
involving the addition of 350 µl internal standard (I.S.) solution (100 ng/ml 
GSK334429B as internal standard in 80% ACN with 20% 10 mM ammonium acetate).  
A total blank was included in each standard line where I.S. solution was added without 
I.S. compound to ensure there was no carry-over of analysed compounds.  The tubes 
underwent vigorous shaking for 20 min and centrifugation for 15 min at 3220 g at room 
temperature before LCMSMS analysis was performed directly from the supernatant 
solution. 
For all LCMSMS analysis, samples were introduced with a CTC Analytics HTS 
Pal autosampler (Presearch, UK) to an Agilent 1100 series binary pump (Waldbronn, 
Germany) HPLC system interfaced with an API4000 triple quadrupole mass spectrometer 
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equipped with a Turbo Ionspray (TIS) interface (Applied Biosytems, Ontario, Canada).  
All runs were carried out with the column thermostat set to 40
o
C, an eluent flow rate of 1 
ml/min and 2 min run time, using mobile phases 10 mM ammonium acetate with 0.1% 
formic acid (Solvent A) and ACN (Solvent B).  Positive ionization mode was used with 
TIS source temperature, 690°C; TIS voltage, 5500V; curtain gas, 20 psi; nebulizing 
(GS1), 50 psi; TIS (GS2) gas, 70 psi; collision activated dissociation (CAD) gas, 4 psi.  
HPLC, MSMS conditions and cassette groupings for all compounds analysed are listed in 
Table 4. 
Peak quantification and was carried out in Analyst® software (Applied 
Biosystems, CA, USA) and all standards had to pass ±20% acceptance criteria for runs to 
be accepted.  Peak area ratios (analyte:IS) were quantified against the calibrated standard 
concentration line obtained using 1/x
2
 weighted linear regression enabling calculations of 







Table 4. HPLC and MSMS conditions 
 
Abbreviations: 
Ari – Aricept Ver – Verapamil 
Tac – Tacrine Dex – Dextromethorphan 
Mem – Memantine 7-EC – 7-ethoxycoumarin 
Gal – Galantamine Cyano – Discovery Cyano HPLC column (5cm x 4.6mm, particle size 5m, Supelco, Sigma Aldrich, USA) 
Rsv – Rosuvastatin B – ACN mobile phase 
Tes – Testosterone Hypurity – Hypurity C18 column (5cm x 4.6mm, particle size 5m, Thermo Scientific) 
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3. 3. 5 Measurement of renal and biliary excretion capacity 
Young and old rats (n=6) were dosed with either Memantine or Rosuvastatin 
at 5 mg/kg and 5 ml/kg with 1% methyl cellulose as vehicle.  They were housed 
individually in metabolic cages (supplied by Dr Eric Chan, NUS Pharmacy) and urine 
and faecal samples were collected over 24 h.  Memantine was used as a marker for 
renal excretion capacity as it is excreted primarily through the kidney and partly by 
tubular secretion in rat and human (European public assessement report, Ebixa®).  
Rosuvastatin was used as a marker for biliary excretion as it was reported that 98% of 
the dose was excreted in faeces mainly as unchanged compound (Nezasa et al., 2001).  
Urine collection was carried out in dry ice preventing destabilization of the compound 
whereas faecal collection was carried out at room temperature (22°C).  Samples 
collected were stored at -80°C until LCMSMS analysis. 
3. 3. 6 Sample preparation and LCMSMS analysis conditions for Memantine and 
Rosuvastatin in urine and faecal samples 
For analysis of urine samples, a 100X dilution was deemed appropriate for 
analysed concentration to fall within a quantifiable range of 50-5000 ng/ml based on 
prior excretion data (Kornhuber et al., 2007).  Blank rat urine (45 µl) was spiked with 
5 µl of respective drug stock solutions and together with the samples collected, a 
standard procedure of 100X dilution with ddH2O was enforced before sample 
preparation.  Sample preparation was carried out as described in 3.3.4 but without 
addition of ethanol and with Aricept as internal standard.  The same HPLC and MS 
conditions were used for Memantine analysis as described in Table 4. 
For analysis of Rosuvastatin in faeces, a 10X dilution was found to be 
sufficient to reach quantifiable levels (Nezasa et al., 2000).  Faecal samples were 
weighed and homogenized thoroughly in 3 vol of ddH2O with a hand-held 
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homogenizer (PRO200, PRO Scientific, Oxford, CT, USA).  A standard line of 500-
50,000 ng/ml was prepared by spiking 25 µl of blank faecal homogenate with 25 µl of 
respective Rosuvastatin drug stock solutions.  Samples were treated in a similar 
manner with 25 µl of EtOH (representing drug stock solution) added to 25 µl faecal 
homogenate sample.  The same protein precipitation procedure was carried out using 
only 80:20 ACN:ammonium acetate solution.  Tubes were shaken for 20 min and 
centrifuged at 3220 g for 15 min, following which a 5 µl aliquot was taken from the 
top phase and diluted 10X with ddH2O (final volume 50 µl).  I.S. solution (Aricept) 
was then added to the resulting solution and the same shake and centrifuge cycle was 
repeated before final analysis on the LCMSMS.  HPLC and MS conditions can be 
found in Table 4. 
3. 3. 7 Determining CYP450 activity in liver microsomes isolated from aged and 
young LH rats 
Six young and six old LH rats were sacrificed by decapitation and the livers 
were removed, minced, and homogenized on ice with 2 vol of ice-cold homogenizing 
buffer (10 mM EDTA, 150 mM potassium chloride, 0.1 M Tris-Cl, pH 7.4)  in a 
Potter-type homogenizer (RW 20 digital, IKA®Works Asia, KL, Malaysia).  The 
homogenate was centrifuged at 12, 500 g for 15 min at 4°C.  The resultant supernatant 
was ultra-centrifuged at 105, 000 g for 70 min at 4°C and the pellet obtained was re-
suspended in ice-cold pyrophosphate buffer (10 mM EDTA, 0.1 M sodium 
pyrophosphate, pH 7.4) with 5-10 s of homogenization on ice with a hand-held 
homogenizer.  The 105, 000 g ultra-centrifugation step was repeated for 45 min and 
the resulting microsomal pellet was homogenized in 1 ml ice-cold microsome buffer 
(10 mM EDTA, 20% glycerol, 0.05 M Tris-Cl, pH 7.5) and divided into 300 µl 
aliquots.  Protein concentration was determined using Coomassie plus bradford assay 
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kit (Pierce, Rockford, IL, USA) with bovine serum albumin as a reference substance 
and microsome buffer as diluent. The microsome suspension was frozen at -80°C 
until use.  
On the day of assay, drugs were plated into 96-deep well plates in 5 µl 
volumes (final incubation concentration: 0.5 µM from 0.08 mM ACN stocks) and pre-
incubated with 450 µl of microsomes diluted in 50 mM potassium phosphate buffer, 
pH 7.4 (final incubation concentration: 0.5 mg/ml, 0.15 mg/ml used for Testosterone 
due to high clearance rate) in a 37°C shaking water bath for 5 min.  To start the 
reaction, 345 µl of pre-warmed NADPH cofactor was added (final incubation 
concentration: 2.0 mM NADPH, 5.0 mM MgCl2) with phosphate buffer added instead 
to the corresponding no cofactor control wells.  At 0, 5, 15, 25, 35, 45 and 60 min, 75 
µl aliquots were removed from the reaction wells and placed in 150 µl chilled ACN 
on ice to quench the reaction.  For Testosterone, time-points used were 0, 2.5, 5, 7.5, 
10, 15 and 30 min.  Aliquots were taken from the no cofactor control wells only at the 
last time-point.  The plate was then centrifuged at 3220 g for 15 min before analysis 
on the LCMSMS (conditions in Table 4).  Peak area ratios (compound to internal 
standard) obtained were fitted to an unweighted logarithmic decline in substrate using 
Graphpad Prism v5.0 software (La Jolla, CA, USA).  Half-lives and intrinsic 
clearance (CLint) values were calculated with the following equations:  
 Half-life (min) = 0.693 / k  
 CLint (ml/min/g liver) = k * V * Mean mg protein/g liver  
where k = first order rate constant (from Graphpad Prism non-linear regression), 
V = Incubation volume (i.e. 0.8 ml) / mg protein added (i.e. 0.4 or 0.12 for 
Testosterone) 
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and hepatic scaling factor of 52.5(in-house value) was used for mean mg protein/g 
liver. 
3. 3. 8 Quantification of P-glycoprotein mRNA expression using Taqman real-time 
PCR 
The same rats used for liver microsome isolation were used here.  Brains were 
removed, halved and sectioned into distinct regions (cortex, cerebellum, hippocampus 
and striatum) and immersed in RNA Later tubes (Qiagen, Duesseldorf, Germany).  
Sections weighing ~100 mg from liver, kidney and intestine (removed and flushed 
with cold saline before section taken from middle portion) were removed and put into 
RNA Later tubes.  Samples were homogenized using the TissueLyzer (Qiagen) for 2.5 
minutes at frequency 30.  The samples were alternated within the 24 slot rack and the 
process repeated for proper homogenization. 
Total RNA isolation from the various tissues was carried out with the 
RNAEasy Lipid Mini Kit (Qiagen) with the optional stage of digestion by DNase 
(RNase-Free DNase Set, Qiagen) added according to the Qiagen extraction protocol.  
Spectrophotometric quantification of total RNA was performed with the Nanodrop 
(Thermo Fischer Scientific, Wilmington, DE, USA) and RNA was diluted to 100 
ng/µl.   
cDNA was prepared with a High Capacity Reverse Transcription Reagent Kit 
(Applied Biosystems).  Briefly, 10 ul of diluted RNA was added to a mastermix 
containing random primers, dioxyribonucleotide triphosphate (dNTP) mix, reverse 
transcriptase, RNase inhibitor, RT buffer and water at volumes specified by the 
manufacturer’s instructions giving a final volume of 20 µl.  Incubation was carried 
out in a thermal cycler (Applied Biosystems) at the following conditions: 
Temp (°C)  25  37  85  4 
Time (Min)  10  120  5 sec  Infinity 
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 The cDNA produced was diluted 4X with Rnase-Dnase free water (Qiagen) 
and 4 µl was dispensed onto Taqman plates (MicroAmp, Applied Biosystems).  
Respective mastermixes containing the appropriate probes and primers was added to 
produce a final volume of 20 µl.  Primers and probes specific for ABCB1a, ABCB1b 
(sequences obtained from Balayssac et al., 2005) and cyclophilin (housekeeping) were 
obtained from 1
st
 Base Oligos (see Table 5 for sequence) and assay mastermixes for 
GAPDH and beta-actin (housekeeping) were purchased from Applied Biosystems.  
Real-time PCR was carried out in the Applied Biosystems 7500 Fast Real-Time PCR 
System with cycling conditions: hot start at 95°C for 20 s → [95°C for 3 s → 60°C 
for 30 s, 40 cycles].  Gene expression was quantified against genomic DNA standards 
and statistical methods performed using the Taqman Toolkit v2.11 (in-house 
Microsoft Excel Add-In developed by PRISM training and consultancy Ltd in 
collaboration with ReversePharma Ltd.).   
Genes Sequence 
ABCB1a forward: 5’-TCT GGC GGC CAT TAT CCA T-3’ 
reverse: 5’-TCA TAC TAC GGT TGT TTC CTA CAT TTG-3’ 
probe: 5’-ATT GCG CTC CCA CTT ATG ATG CTG GTC T-3’ 
ABCB1b forward: 5’-TGA ATC CCA AAG TGA CAC TGG T-3’ 
reverse: 5’-ATA CTT CTG CGA ATT GAT CTC CTT ATT-3’ 
probe: 5’-CCT CTG AGT TGA CTT CAG AAG AAT CAA AAT 
CTC CTT-3’ 
Cyclophilin  forward: 5'-TTA TCT GCA CTG CCA AGA CTG A-3'  
reverse: 5'-CCA CAA TGC TCA TGC CTT CTT TC-3'  
probe: 5'-CCA AAG ACC ACA TGC TTG CCA TCC A-'3 
Table 5. Primer and probe sequences for ABCB1a, ABCB1b and housekeeping 
gene, cyclophilin 
 
  27 
3. 4 Pharmacodynamic-based Assays 
3. 4. 1 Measuring ChE activity in brains of ChEI-dosed animals 
ChE activity was measured using Ellman’s colorimetric assay (1961) modified 
into a high-throughput 96-well plate format by Padilla et al., (1998).  For assay of 
AChE and BChE ex vivo, half-brains collected previously from animals dosed with 
Aricept, Tacrine, Galantamine and vehicle (see 3.3.2) were homogenized in 10 vol of 
0.1 M Na phosphate buffer (pH 8.0) and 1% Triton (homogenizing buffer).  The 
homogenate was centrifuged for 10 min at 1000 g at 4°C and protein from supernatant 
was quantified with a BCA protein assay kit (Pierce, Rockford, IL, USA) to ensure all 
samples contain approximately similar protein levels.  Supernatant was kept at -80°C 
in aliquots.   
On the day of assay, neat plasma (5 µl) or brain preparations diluted 5X with 
homogenizing buffer (10 µl) were pre-incubated at 37°C for 10 min with 0.33 M 
DTNB (Sigma Aldrich) in 0.1 M sodium phosphate buffer (pH 8.0) (working buffer).  
In wells where only AChE activity was to be measured, 10 µl of iso-OMPA (selective 
BChE inhibitor, Sigma Aldrich) was included (final concentration in well: 0.1 mM).  
After pre-incubation, 10 µl of substrate, acetylthiocholine iodide (ACthI, Sigma 
Aldrich), was added to the wells (final concentration in well: 1 mM).  The plate was 
immediately put in a microplate reader (Infinite®F500, Tecan, Switzerland) heated to 
37°C and read in a kinetic format with the plate set to shake for 5 s followed by a read 
at 412 nm, this process repeating every 2 min up to 12 min (6 reads).  Tissue and 
substrate blanks were included for every plate which excluded brain 
homogenate/plasma and ACthI respectively.  All samples were done in triplicate 
wells.  Final volume in each well: 200 µl.   
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To measure cholinesterase activity in vitro, vehicle-dosed rat plasma and brain 
homogenate were incubated with increasing concentrations of Aricept, Tacrine or 
Galantamine at 10 µl volumes.  Concentrations used were based on previous literature 
of their obtained Ki values in rat (Ogura et al, 2000; Geerts et al., 2005) and by trial 
runs performed.  Substrate ACthI was added after the preincubation step and the same 
kinetic read format used previously was employed.   
For calculation of activity, the mean of the slopes (change in absorbance per 
min, ∆A/min) for each triplicate set of samples was taken and converted to 
µmol/min/ml (plasma) or µmol/min/g (brain) with the following equation: 
 
Activity = [(Average ∆A - ∆Ablank)/min] / factor(∆A/-SH nmol) / sample vol (ml) / 
sample dilution (1 for plasma, 55 for brain) / 1000 (nmol to µmol) 
where factor is an instrument-specific calculation factor determined by establishing a 
free sulfhydryl standard curve that measures ∆A per unit of –SH. 
 
BChE activity was calculated by taking total ChE activity minus residual activity in 
the presence of the specific BChE inhibitor (i.e. AChE activity).   
3. 4. 2 Observation of cholinergic-mediated behaviour in Tacrine-dosed animals 
Young and old animals (n=6) were dosed orally with Tacrine at 10 mg/kg and 
30 mg/kg at 5 ml/kg dose volume with 1% methyl cellulose vehicle that was given 
alone to a control group of animals.  Doses were given in a random fashion and 
grading of behaviour was made by a person unaware of the treatment administered.  
Behavioural grading of tremor and lacrimation was carried out on a 0-3 scale as 
shown in Table 6 which was used previously by Dronfield et al. (2000).  Temperature 
was taken by means of a rectal probe (Bioseb, Chaville, France) inserted by 5 cm into 
the rectum which gave a steady reading within 10 s that was promptly recorded.  
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Salivation was measured by collecting saliva on a pre-weighed cotton bud by wiping 
the bud in and around the mouth for 6 s and reweighing it.  Responses were recorded 
prior to dosing and 0.5, 1, 2, 4 and 6 h after dosing.  
 0 1 2 3 
Tremor no tremor obvious tremor 
in two limbs or 
slight tremor 
in four limbs 
obvious tremor 

















Table 6. Grading scale of cholinergic behaviour for tremor and lacrimation 
3. 4. 3 Quantifying expression of muscarinic acetylcholine receptors in brain by 
immunoblotting 
Six young and six old rat half-brains were dissected free of meninges and 
white matter before gentle homogenization with a glass and mortar (ten plunges) in 1x 
CST lysis buffer (Cell Signalling Tech Inc., Beverly, MA, USA) with protease 
inhibitors, AEBSF (Sigma Aldrich) and one complete mini Roche tablet (Roche 
Applied Science, IN, USA).  Sample buffer (Laemmli Sample buffer, Bio-rad, CA, 
USA) with 2-mercaptoethanol was then added to the samples, followed by boiling at 
100°C for 3-5 min to denature proteins.  The samples and a precision plus dual colour 
protein standard (#161-0374, Bio-rad, 0-250 kDa range) were loaded in 10% 
polyacrylamide gels and electrophoresis was carried out at 120 V for 1 h.  Transfer 
took place onto nitrocellulose membranes and these were blocked in 10 mM 
phosphate buffered saline (pH 7.4), 0.1% Tween 20 and 5% skim milk (PBSTM) 
before immunoblotting with primary antibody in PBSTM with 5% BSA at 1:1000 
overnight at 4°C.  Primary antibodies used for M1 mAChRs (rabbit polyclonals) were 
from Alomone labs (Jerusalem) while M2-M4 mAChR antibodies (rabbit polyclonals) 
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were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).  Following 
washings in PBSTM and incubation with horseradish peroxidase conjugated 
secondary antibodies (1:10, 000, Jackson ImmunoResearch Inc., West Grove, PA), 
immunoreactive bands on the membranes were detected by enhanced 
chemiluminescence and quantified by an image analyzer (UVItec, Cambridge, UK). 
Membranes were then stripped and re-blotted with anti-β-actin (1:5, 000, mouse 
monoclonal, Sigma-Aldrich) to control for sample loading across lanes.  Normalized 
immunoblot optical densities are expressed in arbitrary units.  
3. 4. 4 NMDA receptor radioligand binding assay with [3H]MK-801 to determine 
changes in receptor expression and binding affinity to Memantine 
Five young and five old LH rats were decapitated and brains removed rapidly 
and frozen at -80°C.  For preparation of crude brain membranes, brains were thawed 
and cerebellum removed.  The tissues were homogenized in 10 vol of ice-cold 1 mM 
EDTA and 0.32 M sucrose with an ultrasonicating homogenizer and centrifuged at 
1000 g for 10 min at 4°C.  The supernatant obtained was centrifuged at 45, 000 g for 
20 min at 4°C and the resulting pellet was resuspended in 20 vol (original tissue 
weight) of ice-cold 5mM Tris HCl (pH 7.4) and homogenized with a hand-held 
homogenizer for 10-15 s.  Homgenates were incubated at 37°C for 30 min to get rid 
of endogenous glutamate following which they were centrifuged again at 45 000 g for 
20 min at 4°C.  Pellets were resuspended as before and the spin and resuspend process 
was repeated an additional two times to wash the membranes.  The final pellet was 
suspended in 5 mM Tris HCl (pH 7.4) and protein was quantified with BCA kit 
(Pierce) before storing in 1 ml aliquots at -80°C till use. 
In saturation and competition binding studies, assay buffer of 10 µM L-
glutamate and 10µM glycine in 5 mM Tris HCl (pH 7.4) was used to stimulate 
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binding of [
3
H]MK-801 (Perkin Elmer, MA, USA).  Non-specific binding was 
determined with 1 µM of unlabeled (+)MK-801 (Sigma Aldrich).  Brain membranes 
were incubated with radioligand at room temperature (25°C) for 2 h in deep well 
plates at 0.5 ml volume and approximately 70-100 µg of membrane protein per well.  
Incubation was stopped by filtration with filter paper soaked in 0.3% 
polyethyleneimine (PEI) and membranes retained on the filters were rinsed four times 
with ice-cold 5 mM Tris-HCl buffer.  To obtain a saturation curve for [
3
H]MK-801, 
concentrations from 0.39 to 50 nM were used.  For all competition binding assays, a 
fixed concentration of 5 nM [
3
H]MK-801 was used.  Concentration of Memantine 
used ranged across ten log units from 4 nM to 12.6 µM.  Competition binding was 
also carried out with unlabelled MK-801 with concentrations ranging from 0.03 nM to 
949 nM. 
3. 5 Statistical Analysis 
In Taqman Toolkit analysis of real-time PCR results, all housekeeping genes 
were combined to give a single normalization value using PCA analysis.  ANCOVA 
was performed on all genes using the PCA-1 as co-variant.  Dunnet’s post-hoc 
analysis carried out to test statistical significance.  All other statistical analysis was 
performed using Statistica (StatSoft Ltd, Bedford, UK).  Comparisons between young 
and aged groups were made using unpaired/independent t-tests.  General age and 
treatment effects across groups were analysed with two-way ANOVA.  A one-way 
ANOVA followed by a Dunnet post-hoc test was used to compare variance of 
treatment groups from control group (ex vivo cholinergic activity).  For repeated 
measurements (e.g. cholinergic grading or IV/PO PK profiles), a repeated measure 
ANOVA was employed with planned comparisons made between groups to 
demonstrate treatment or age effects. 
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4 Results 
4. 1 Pharmacokinetic-based assay results 
4. 1. 1 Pharmacokinetic intravenous (IV) 6h profiles  
Out of the four drugs tested, only Galantamine showed a notably different 
concentration-time profile on 1 h IV infusion at 1 mg/kg and 10 ml/kg (fig. 1).  
Significantly higher blood concentrations of drug were reached in the old rats from 
0.25 to 2 h with a Cmax 42% greater than that in the young group.  Following which, 
drug concentrations declined to similar levels as seen in the young rats (fig. 1d).   For 
the other drugs, concentration-time profiles were similar between young and old rats, 
with slight but significant differences in concentrations seen at certain time-points 
(fig. 1a, b, and c).   
PK parameters obtained from non-compartmental analysis of the 
concentration-time profiles can be viewed in table 7.  Despite the higher maximal 
blood concentration (Cmax) observed in Galantamine-dosed old rats, the increase in 
area under concentration-time-curve (AUC) did not reach a significant level due to the 
greater variability seen in the old rats.  Clearance (Clb) and half-life (t1/2) showed a 
trend towards decreasing with age, but only the drop in volume of distribution (Vd) 
reached significance (Table 7).   A decline in Vd on ageing increases the amount of 
drug in the circulating blood compartment.  This explains the higher blood 
concentrations seen in the initial phase of the Galantamine profile.   
In contrast with Galantamine, significant increases in Vd of Aricept and 
Memantine were found in the old rats.  This was observed to affect the concentration-
time profile of Aricept, where a greater distribution into tissue compartments during 
the initial stage of infusion resulted in the slightly lowered systemic blood 
concentrations observed in the old rats (fig. 1a).  The larger Vd also meant a longer 
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time was taken for Aricept to dissociate from its wider distribution in tissues, 
contributing to the significant prolonging of t1/2 by about 1.5 fold (table 7).  This, 
along with a potential decrease in Clb may have resulted in the higher levels of drug 
seen in blood of old rats during the later time-points of the profile (fig. 1a).  Changes 
in Memantine concentration-time profile were not as discernable. 
A two-way ANOVA performed analysing age and treatment effect indicated 
that both factors had a significant impact on all PK parameters.  A decrease of Clb and 
an increase in extrapolated AUC per unit dose (AUC0-∞/Dose) with age was observed 
across all treatment groups which did not interact with treatment effect.  But it should 
be noted that larger extrapolations were made for concentration-time profiles of 
Aricept and Memantine as they did not reach baseline levels at 6 h (table 7).  As PK 
parameters were obtained from the extrapolated concentration-time curves, caution 
should therefore also be taken when interpreting changes in PK parameters due to age 
for Aricept and Memantine.  Other PK parameters such as Cmax, Vd and t1/2, reported 
interactive effects between age and treatment primarily due to the different directional 
changes in Vd across treatments and age groups (fig 2). 
4. 1. 2 Pharmacokinetic oral (PO) 6h profiles 
Oral dosing commonly results in a more variable concentration-time profile 
due to differing extents of the first-pass effect between animals.  This was observed in 
the PO PK profile performed where higher standard deviations were obtained 
compared to IV PK profiles.  Previously mentioned changes in Vd due to age 
however could be observed in the PO concentration-time profiles where a decrease in 
Vd of Galantamine with age gave rise to a trend of higher systemic blood 
concentrations in the first 2 h following dosing (fig. 3d).  And an increased Vd of 
Aricept and Memantine led to a tendency for lower systemic blood concentrations in 
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the first 1.5-2 h post-dose (fig. 3a and c).  Old rats dosed with Aricept and Tacrine 
showed significant but slight increase of blood drug concentrations at certain time-
points with a delayed return back to basal levels (fig, 3a and b).  This could be 
indicative of a decline in clearance, although no significant change in AUC was 
detected (table 8).  No significant changes were detected with age for all PK 
parameters obtained, including bioavailability.  And a two-way ANOVA did not 
detect any trend of age-related changes in PK parameters when looking across all 
treatments.  An interactive effect however between age and treatment was observed 
for Cmax (fig. 4) which can be attributed to the different effects of age on Vd for the 
respective drugs. 
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Figure 1.  Concentration-time profiles following intravenous infusion of gold 
Standard AD drugs in young and old LH rats (1mg/kg, 10ml/kg/h).  Points represent 
mean ± SD, n=3 except Aricept old group, n=5 and Galantamine young group, n=2.  
Repeated measure ANOVA was performed and planned comparisons between young 
and old groups reported significant difference (p < 0.05) at time-points (*) and from 
0.25-2 h in Galantamine profile.    
  ●    Young;      Old  






Aricept Tacrine Memantine Galantamine 




















52 ± 7 43 ± 5 93 ± 9 77 ± 8 35 ± 4 34 ± 4 43 ± 2 34 ± 6 
Vd (L/kg) 9.2 ± 0.6 
11.8 ± 
0.8** 
5.1 ± 0.5 5.2 ± 0.7 7.3 ± 0.6 
9.6  ± 
1.0* 
5.3 ± 0.4 
2.9 ± 
0.1** 
t1/2 (h) 2.5 ± 0.3 
3.6 ± 
0.3** 
































23.4 ± 1.0 
29.9 
± 5.3 
% extrapolation 18 ± 3 30 ± 3 5 ± 2 5 ± 2 22 ± 4 31 ± 7 10 ± 0 7 ± 3 
Table 7. PK parameters of gold Standard AD drugs in young and old LH rats 
obtained from IV PK profile 
Values are mean ± SD.  t for AUC (0-t) is 6 h or time of last quantifiable 
concentration; other abbreviations explained in text.  Independent t-tests performed 
showed significance between young and old groups (* p < 0.05, **p < 0.01).  A two-
way ANOVA performed (factors: age, treatment) indicated age having a non-
interactive significant effect on PK parameter (#p < 0.05, ##p < 0.01). 
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Treatment*Age; LS Means
Current effect: F(3, 17)=6.2491, p=.00469
Effective hypothesis decomposition



























Current effect: F(3, 17)=14.838, p=.00005
Effective hypothesis decomposition























Current effect: F(3, 17)=1.4889, p=.25321
Effective hypothesis decomposition


























Current effect: F(3, 17)=6.5694, p=.00378
Effective hypothesis decomposition

























Current effect: F(3, 17)=3.7879, p=.03008
Effective hypothesis decomposition
































Current effect: F(3, 17)=.91396, p=.45503
Effective hypothesis decomposition




































Figure 2. Effect of age and treatment on PK parameters obtained from IV PK 
profiling.  Graphical output from Statistica software where a two-way ANOVA was 
performed analysing factors of age and treatment.  P-values indicate the interactive 
effect between the two factors. 
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Figure 3.  Concentration-time profiles of gold Standard AD drugs in young and old 
LH rats dosed orally (3mg/kg, 5ml/kg).  Points represent mean ± SD, n=3 except 
Aricept old group, n = 5.  Repeated measure ANOVA was performed and planned 
comparisons between young and old groups reported significance (p < 0.05) at certain 
time-points (*).            
  ●    Young;       Old   
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PK parameter 
Aricept Tacrine Memantine Galantamine 






































































Fpo (%)  36 ± 10 43 ± 8 27 ± 7 29 ± 2 56 ± 12 51 ± 10 83 ± 13 67 ± 10 
Table 8. PK parameters of gold Standard AD drugs in young and old LH rats 
obtained from PO PK profile 
Values represent mean ± SD.  Tmax expressed as median and range; Fpo represents 
bioavailability, Fpo calculated for Galantamine-dosed young rat 3 using average 
AUCiv from young rat 1 and 2.  Independent t-tests performed showed no significant 
differences in PK parameters between young and old groups. A two-way ANOVA 
performed revealed that age had no significant effect on all PK parameters. 
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Treatment*Age; LS Means
Current effect: F(3, 18)=3.7510, p=.02971
Effective hypothesis decomposition



























Current effect: F(3, 18)=.86124, p=.47908
Effective hypothesis decomposition


































Current effect: F(3, 18)=.71625, p=.55506
Effective hypothesis decomposition


































Current effect: F(3, 18)=.69100, p=.56933
Effective hypothesis decomposition




























Figure  4. Effect of age and treatment on PK parameters obtained from PO PK 
profiling.  Graphical output from Statistica software where a two-way ANOVA was 
performed analysing factors of age and treatment.  P-values indicate the interactive 
effect between the two factors. 
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4. 1. 3 In vivo brain permeability  
Graphical representations of blood and brain concentrations and brain:blood 
ratios in young and old rats after oral dosing at 3 mg/kg with the gold standard AD 
drugs can be seen from fig. 5, with actual values shown in table 9.  A two-way 
ANOVA revealed a statistically distinct trend of higher blood and brain drug 
concentrations in the old rats compared to the young rats across treatments at 1 h post-
dose.   
Independent t-tests comparing young and old groups for each treatment 
identified statistically significant increases in brain concentrations for only Aricept 
and Memantine (1.8 fold and 1.4 fold respectively) (fig. 5b).  Memantine exhibited an 
accompanying significant increase in blood concentration in the old rats (fig. 5a).  The 
increased blood concentrations of Aricept and Memantine at 1 h post-dose here lies in 
contrast with the previous result obtained in the PO profile study where levels were 
lower instead.  This may be attributed to inter-animal variability in drug absorption 
following PO dosing which is known to be greater as compared to other routes such 
as the IV route. 
Brain:blood ratios were found to be similar in young and old rats for all drugs 
tested (fig. 5c), indicating a maintenance in integrity of the blood brain barrier with 
age.  It can also be observed from the results that Memantine showed the highest brain 
permeability (represented by brain:blood ratio, fig. 5c), followed by Tacrine, Aricept 
and Galantamine in order of decreasing brain permeability. 
4. 1. 4 In vitro brain:blood prediction studies to evaluate plasma protein binding 
and tissue binding 
It should be noted that blood and brain tissue used in this assay was from 1 old 
and 1 young rat only and due to a shortage of aged rats, more assays could not be 
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performed.  Therefore, changes observed here may not be sufficient to suggest a 
general change with age in the LH rat.   
Fig. 6a shows the % free fractions of the drugs in blood.  Galantamine was 
seen to have the highest levels of drug free fractions (76% in young rat) while Aricept 
had the lowest free fractions of drug (27%, Table 10).  This correlates well with their 
plasma protein binding properties found in man (Aricept 96% bound, Galantamine 
18% bound, table 3).   Upon ageing, % free fraction blood levels of all drugs did not 
change substantially and no uniform trend of increase or decrease across all groups 
was seen.  This suggests that the extent of drug binding to blood components which 
include plasma proteins is maintained with age in the old LH rat. 
From fig. 6b, Galantamine showed the highest % free fraction levels in brain, 
demonstrating its low binding affinity to brain tissues, likely relating to its lower 
lipophilicity compared to the other drugs (refer table 3 for clogP values).  Minor 
changes of % free fraction in brain tissues were also observed on ageing for all drugs. 
Similar to in vivo results, in vitro brain:blood partition co-efficient (Kbb) of 
young and old rats did not differ substantially.  A fairly accurate representation of in 
vivo brain permeability was achieved in the in vitro assay with successful prediction 
of Memantine having the highest brain permeability and Galantamine the lowest 
among all the drugs.  For Aricept however, overestimation of brain:blood ratio 
occurred.  A key reason may lie in the in vitro assay assumption that compounds are 
not subject to transport processes. Aricept has been shown to have P-gp substrate 
activity (Ishiwata et al., 2007) which would have resulted in its increased efflux from 
the brain, accounting for its lower brain permeability in vivo. 

















































































































































Young Old Young Old Young Old 
Aricept 0.13 ± 0.01 0.21 ± 0.11 0.57 ± 0.09 1.02 ± 0.23* 4.4:1 ± 0.3 5.3:1 ± 1.8 
Tacrine 0.11 ± 0.03 0.19 ± 0.12 1.24 ± 0.30 1.72 ± 0.93 11.0:1 ± 1.2 9.5:1 ± 0.7 
Galantamine 0.42 ± 0.02 0.58 ± 0.21  0.73 ± 0.04 1.14 ± 0.39 1.7:1 ± 0.2 2.0:1 ± 0.0 
Memantine 0.68 ± 0.10 1.02 ± 0.10* 13.12 ± 1.16 
18.88 ± 
1.27** 
19.3:1 ± 1.0 18.7:1 ± 1.5 
Table 9. In vivo blood, brain concentrations and brain:blood ratio values of gold 
Standard AD drugs in young and old LH rats after PO administration 
Values are mean± SD.  Corrected brain concentration refers to measured brain 
concentration minus vascular volume of blood present in brain which is estimated to 
be 1.5% of blood concentration.  Independent t tests performed between young and 
old groups (*p < 0.05, **p < 0.01).  Two-way ANOVA performed showed significant 
effect due to treatment (┼) and age (#) with both p < 0.001.  
 
Figure 5. In vivo blood (a), brain 
concentrations (b) and brain:blood ratios 
(c) of Gold standard AD drugs in young 
and old LH rats dosed orally at 3mg/kg 
and culled 1h later. Bars represent means 
with error bars showing SD. n=3 with 
exception of Galantamine old group, n=2. 
Independent t-tests performed indicated 
significance between young and old 
groups (*p < 0.05, **p < 0.01) 


















































































































% free fraction (blood) % free fraction (brain) Kbb 
Young Old Young Old Young Old 
Aricept 27 24 9 10 3.0 2.5 
Tacrine 40 29 18 17 2.3 1.7 
Galantamine 76 81 82 64 0.9 1.3 
Memantine 36 37 7 9 5.4 4.2 
Table 10. In vitro % free fractions of gold Standard AD drugs in blood and 
brain and Kbb values in young and old LH rat 
Values represent mean of 6 well replicates, n=1 
 
Figure 6. In vitro % free fraction of 
Gold Standard AD drugs in blood 
(a), brain (b) and in vitro 
Brain:Blood predictor, Kbb (c) in 
young and old LH rat. Bars represent 
means of 6 replicate wells per rat, 1 
old rat and 1 young rat used in total. 
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4. 1. 5 Renal and biliary excretion capacity changes with age 
To estimate the renal and biliary excretory capacity of rats, Memantine and 
Rosuvastatin were chosen as markers of renal and biliary function respectively as they 
do not undergo extensive metabolism in humans and rats and are excreted mostly as 
unchanged drug enabling easier detection with LCMSMS (Kornhuber et al., 2007, 
Nezasa et al., 2002).  In addition, Memantine is partly cleared via tubular secretion, 
providing an overall assessment of renal integrity. 
Fig. 7 shows the amount of excreted drug represented as a percentage of 
bioavailable drug (i.e. amount of drug in systemic circulation after the first-pass effect 
following oral administration) in young and old rats.   For Memantine, no significant 
difference in % of bioavailable drug excreted in urine was observed between the 
young and old rats.  The % of bioavailable Memantine excreted ranged from 7.7% to 
23.9% with the old rats showing a wider spread of data.  This demonstrates a lack of 
substantial renal impairment upon ageing in the LH rat. 
For Rosuvastatin, the old rats showed a significantly lower % of bioavailable 
drug excreted in faeces compared to the young rats.  Bioavailability values used for 
Rosuvastatin however, due to lack of old animals, were obtained from prior literature 
and not differentiated between young and old rats (table 11).  Therefore, the 
difference detected in % excreted may be due to differences in oral absorption, 
metabolism and distribution rather than changes in biliary excretory capacity.   A 
study in humans however, has shown that age did not have a clinically relevant effect 
on the PK of Rosuvastatin (Martin, 2002).   
The amount of excreted Memantine and Rosuvastatin found in LH rat urine 
and faeces was lower than previous reports in rats (80-90% of dose excreted for both 
drugs, EMEA Memantine, Nezasa et al., 2002). The method of detection used 
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previously however involved measuring excreted radioactivity of radiolabelled 
compound.  Metabolites containing the radiolabel could therefore have accounted for 
the high amount excreted, whereas LCMSMS detection used here would only 
quantify amount of parent compound which may be present in lesser amounts.  Strain 
differences may also have accounted for the differences observed as prior experiments 
were done in Sprague-Dawley rats. 



























































































Figure 7. Renal and biliary excretory capacity in young and old LH rats represented 
by amount of Memantine (a) and Rosuvastatin (b) found in urine and faeces 
respectively.  Rats dosed with 5 mg/kg of compound and samples collected over 24 h.  
Points represent individual rat values with mean indicated by black line and error bars 
representing SD, n=6 except for young Rosuvastatin-dosed group, n=5.  ● Young;  
Old.  Independent t-test performed reported significant difference between young and 
old groups for excretion of Rosuvastatin only (**p < 0.01). 
 
 
Compound Age group Bioavailability (%) 
Mean % of bioavailable  
drug excreted ± SD 
Memantine 
Young 56 11 ± 3 
Old 51 13 ± 6 
Rosuvastatin 
Young 20 24 ± 3 
Old 20 17 ± 3** 
 
Table 11. Bioavailability of Memantine and Rosuvastatin used in calculation of 
% bioavailable drug excreted 
Bioavailability values for Memantine were obtained from PO PK profiles done on 
young and old LH rats (see Table 8).  Bioavailability value for Rosuvastatin obtained 
from literature which used 2mth old male Sprague-Dawley rats (Nezasa et al., 2002), 
therefore not age-adjusted. **p < 0.01 vs. young group (independent t-test). 
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4. 1. 6 Changes in CYP450 activity in microsomes isolated from aged and young 
LH rats 
In vitro metabolic clearance of all drugs tested with the exception of 7-
ethoxycoumarin and Memantine were seen to generally decline on ageing (fig. 8).   
CYP probe drug Verapamil saw the largest decline in in vitro metabolic clearance 
with a 46% drop in CLint (table 12).  As it is metabolized by CYP3A and CYP1A 
enzyme isoforms, this suggests that ageing results in a decrease in either or both 
enzyme activities.  This is supported by the observation that other CYP3A substrates, 
Dextromethorphan and Testosterone, also underwent a significant decrease in CLint on 
incubation with aged liver microsomes (33% and 29% decrease respectively).  A 39% 
drop in CLint of Tacrine upon ageing, implies that CYP1A activity decreases on 
ageing alongside CYP3A. 
Aricept was seen to have a more gradual metabolic clearance curve on 
incubation with old rat liver microsomes (fig. 8e) but the decrease in CLint and 
prolongation of half-life reported did not reach significant levels (table 12).  Its 
greater stability compared to Dextromethorphan which has a similar CYP enzyme 
activity profile may be due to its binding to microsomal proteins, limiting the amount 
of free drug available for metabolism.  Aricept is also known to have a low rate of 
binding to CYP enzymes compared with Dextromethorphan resulting in the latter 
being more rapidly and extensively metabolized (Wilkinson, 1999).  Another CYP2D 
and 3A substrate, Galantamine, was seen to be very stable during incubation with the 
detected fall in drug levels being insufficient in magnitude and too variable for the 
appropriate estimation of half-life and CLint values.  This too may be due to a low 
binding affinity to CYP enzymes although this has not been reported. 
  49 
Memantine reported no change in metabolic clearance on ageing, correlating 
with its minimal interaction to CYP enzymes although a decline in compound was 
still detected over time.  This could possibly be due to interaction with CYP2B as 
Memantine was shown to be a potent selective inhibitor of human recombinant 
CYP2B6 in in vitro assays (Micuda et al., 2004).   
The O-deethylation of 7-ethoxycoumarin is catalysed by enzymes from the 
CYP1, 2 and 3 families and is widely used as a general assay to characterize CYP 
activity (Waxman and Chang, 2006).  In vitro metabolism of 7-ethoxycoumarin 
varied considerably among rats and a change in activity on ageing was not clearly 
detected.  As such, activities of some CYP enzyme subtypes may be maintained or 
even upregulated with age despite the general decline in activity seen for CYP3A and 
CYP1A.  The degree of impact from ageing is therefore dependent on the compound’s 
CYP specificity and the extent of their association. 
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Figure 8. In vitro metabolic clearance of CYP450 probe drugs (a-d) and gold 
Standard AD drugs (e-h) by liver microsomes isolated from old and young LH rats.  
Data are peak area ratio (compound:internal standard, IS) and represented as mean ± 
SD (n=6).  
  ●    Young;      Old  






Age Half-life (min) CLint (ml/min/g liver) 




5.3 ± 1.1 
 
10.0 ± 2.3** 
14.1 ± 2.7 
 
7.6 ± 1.7*** 




2.9 ± 0.4 
 
4.7 ± 1.7* 
25.5 ± 3.7 
 





16.4 ± 2.1 
 
15.1 ± 6.2 
4.5 ± 0.6 
 





1.8 ± 0.1 
 
2.9 ± 1.1 
132.9 ± 8.9 
 
94.2 ± 28.8* 




23.0 ± 1.7 
 
30.3 ± 9.1 
3.2 ± 0.2 
 





21.7 ± 5.9 
 
22.0 ± 6.6 
3.6 ± 0.9 
 





4.9 ± 0.4 
 
9.0 ± 3.4* 
14.9 ± 1.1 
 
9.1 ± 3.5** 
Galantamine 2D, 3A 
Individual metabolic clearance curves were not 
well-fitted as compound was too stable, half-life 
and CLint therefore could not be calculated. 
 
Table 12. Half-life and intrinsic clearance values obtained from metabolic 
stability study of CYP450 probe drugs and gold Standard AD drugs  
Data represented as mean ± SD (n=6, with exception of Aricept old group where n=5 
due to poor curve fit of one sample).  Independent t-tests indicate significant 
difference between old and young groups (*p < 0.05, **p < 0.01, ***p < 0.001).   
Y – Young, O – Old, CLint – Intrinsic clearance.
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4. 1. 7 Quantification of P-glycoprotein mRNA expression  
The mRNA quantification of the two gene isoforms encoding P-gp in rat, 
ABCB1a and ABCB1b, revealed a different tissue profile expression for each gene 
(Fig. 9a and b).  ABCB1a mRNA was expressed at considerably higher levels 
compared to ABCB1b in the cerebellum, cortex and striatum but at equivalent levels 
with 1b in the hippocampus.  It was also more highly expressed in the kidney and 
intestine than the 1b isoform, making ABCB1a the main isoform in these tissues.  
Liver expression of ABCB1b however was 2-fold higher than ABCB1a, although the 
high variability obtained does not exclude a similar level of expression of both 
isoforms in the liver.  Interestingly, ABCB1b mRNA expression in the hippocampus 
was exceptionally high compared to its expression in other brain sections.   
Upon ageing, a general and significant increase in ABCB1b mRNA 
expression was seen across all tissues sampled except for the hippocampus.  This 
increase ranged around 2-fold for these tissues but was considerably increased in the 
kidney by around 5-6-fold (Fig. 9d).  For ABCB1a however, increase in mRNA 
expression was only significant in the cerebellum (1.4 fold increase) while expression 
remained relatively constant in the other brain sections and tissues (Fig. 9c). 
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Tissue expression of ABCB1a and
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Figure 9. Quantification of ABCB1a and ABCB1b mRNA expression in PK relevant 
tissues.  Graphs a and b show ABCB1a and ABCB1b mRNA expression level 
respectively in various tissues and brain sections in young and old rats respectively,  
values represent means with error bars showing upper and lower 95% confidence 
interval.  Graphs c and d show fold change from mean of young control with error 
bars representing upper and lower 95% confidence interval. n=6 was used and 
ANCOVA analysis was done with Dunnet post-hoc test (* p < 0.05, ** p < 0.01, *** 
p < 0.001). 
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4. 2 Pharmacodynamic-based assay results 
4. 2. 1 Ex vivo cholinesterase (ChE) inhibition in brain and plasma 
From fig. 10 and table 12, comparing absolute plasma and brain ChE activity 
levels, total ChE activity was observed to be much higher in the brain (ranging from 
12 to 15 µmol/min/g) compared to plasma (0.4-0.8 µmol/min/ml).  AChE:BChE 
activity ratio was greater in the brain with high AChE and low BChE activity levels 
(12.2) whereas equivalent levels were reported in the plasma (1.2).  On ageing, 
overall ChE activity levels appeared significantly enhanced in the plasma with BChE 
activity increasing to a greater extent (~54%) than AChE (~17%).  Brain ChE activity 
levels in contrast were slightly decreased though not to a significant extent (fig. 10b).   
Upon dosing the young rats with the various ChE inhibitors (3 mg/kg), a small 
but significant inhibition of total ChE activity was seen in plasma and brain for only 
Aricept-dosed rats (fig. 11, table 14).  This inhibition was greater in the plasma than 
in the brain (81.6% vs. 92.6%).  Most part of Aricept’s inhibition was derived from 
AChE inhibition rather than BChE inhibition.  This correlates with the higher potency 
of Aricept with a greater affinity for AChE than BChE among all the other ChE 
inhibitors.  Tacrine was observed to have the greatest BChE-inhibiting effect among 
the drugs which is significantly discernable in the plasma rather than the brain as 
BChE is found at higher levels there.   This corresponds to the greater incidence of 
peripheral side effects reported with Tacrine usage.  Galantamine had the least effect 
on ChE inhibition arising from its lower potency.   
ChE inhibition from application of the drugs was seen to be mostly enhanced 
in the old rats for both plasma and brain tissues (table 14).  Absolute ChE activity 
levels in the plasma however, are still higher in the old rats compared to the young 
despite the greater extent of inhibition (not shown).  An augmented inhibition of 
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plasma BChE by Tacrine and brain AChE by Galantamine in the old animals led to 
significant treatment effects in total ChE inhibition which was previously absent in 
the young rats.   
The enhanced ChE inhibition with age may be ascribed to PK effects.  As the 
same rats were used in the in vivo brain permeability studies, blood and brain 
concentrations can be directly correlated with ChE inhibition response.  Differences in 
blood drug concentrations of the ChE inhibitors were not significantly different 
between young and old rats with only Aricept showing a significant increase in brain 
drug concentrations.  But due to the small magnitude of ChE inhibition enhancement, 
and the trend towards higher blood and brain concentrations observed with age, a PK 
effect cannot be entirely discounted. 
4. 2. 2 In vitro cholinesterase (ChE) inhibition in brain and plasma 
Concentration-response curves of Aricept, Tacrine and Galantamine were 
obtained in vitro on plasma AChE and BChE and brain AChE from vehicle-dosed 
young and old rats.  The results are shown in figure 12 with corresponding IC50 
values represented in table 15.  Due to limited plasma samples, samples were pooled 
and Galantamine concentration-response was not assessed.  BChE activity in brain 
was not represented due to their low amounts present giving rise to high variability.   
No significant change in IC50 values of all drugs for brain AChE was seen 
between young and old rats, while changes in IC50 values of Aricept and Tacrine for 
AChE and BChE in plasma were not dramatic.  This indicates no substantial change 
in intrinsic enzyme properties on ageing which relates to binding affinity of drug to 
target, and subsequent exertion of inhibition.  Due to baseline alterations in ChE 
activity in the old rats however, higher top values of concentration-response curves 
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were seen for all drugs tested on plasma AChE and BChE, while lower top values 
were seen for brain AChE.   
Greater affinity of Aricept towards AChE than BChE was demonstrated once 
again where increasing concentrations of Aricept failed to bring about an inhibition of 
BChE activity in rat plasma.  Previously obtained IC50 value of Aricept for BChE 
was 7400 nM (Ogura et al., 2000) which was out of the range of concentrations used 
here.  The use of tacrine however, provided information on BChE activity changes on 
ageing. 
 










































































Figure 10. Ex vivo cholinesterase (ChE) activity in plasma (a) and brain (b) of young 
and old vehicle-dosed rats culled 1 h post-dose.  Bars represent mean with error bars 
showing SD, n=3.  **p < 0.01, ***p < 0.001 vs. corresponding young group 
(Independent t test). 
 
 
Plasma ChE activity (µmol/min/ml) 
 Young Old 
Total ChE 0.44 ± 0.02 0.71 ± 0.16*** 
AChE 0.24 ± 0.01 0.29 ± 0.04** 
BChE 0.20 ± 0.03 0.42 ± 0.12** 
AChE:BChE Ratio 1.2 0.7 
Brain ChE activity (µmol/min/ml) 
 Young Old 
Total ChE 14.5 ± 0.2 13.3 ± 0.9 
AChE 13.4 ± 0.4 12.4 ± 0.9 
BChE 1.1 ± 0.2 0.9 ± 0.1 
AChE:BChE Ratio 12.2 13.1 
 
Table 13. Ex vivo ChE activities and AChE:BChE ratios in plasma and brain of 
young and old rats. 
Data are mean ± SD, n=3, and represented graphically in fig. 10.  **p < 0.01, ***p < 








































































































































































Figure 11. Percentage inhibition of ChE activity against vehicle in plasma (a) and 
brain (b) of old and young LH rats dosed with Aricept, Tacrine and Galantamine (3 
mg/kg) collected 1 h post-dose.  Bars represent mean ± SD, n=3 with exception of 
Aricept old group (n=2 due to outlier).  #p < 0.05, ### p <0.001 vs. respective vehicle 







 Aricept Tacrine Galantamine 
(% vehicle) Y O 
% change 
(Y – O) 
Y O 
% change 
(Y – O) 
Y O 
% change 
(Y – O) 




68.9 ± 21.9 9.1 97.1 ± 7.4 86.8 ± 7.4 10.3 108.2 ± 3.8 97.3 ± 18.8 10.9 
BChE 90.9 ± 4.8 75.8 ± 19.5 15.1 71.0 ± 13.0 53.5 ± 16.1# 17.5 87.5 ± 26.1 74.9 ± 19.3 12.6 
Brain 
 Aricept Tacrine Galantamine 
(% vehicle) Y O 
% change 
(Y – O) 
Y O 
% change 
(Y – O) 
Y O 
% change 
(Y – O) 
Total ChE 92.6 ± 1.2# 90.0 ± 2.2# 2.6 97.5 ± 1.7 95.0 ± 0.4 2.5 98.7 ± 1.0 88.2 ± 4.3# 10.5* 
AChE 93.5 ± 1.3# 91.5 ± 2.2 2.0 99.2 ± 1.4 96.0 ± 1.3 3.2* 100.1 ± 2.2 89.6 ± 5.1 10.5* 
BChE 81.3 ± 1.2 70.8 ± 8.6 10.5 76.9 ± 5.4 81.9 ± 20.1 -5.0 81.8 ± 13.1 70.2 ± 14.2 11.6 
 
Table 14. Changes in ex vivo ChE inhibition in plasma and brain from young and old rats dosed with Aricept, Tacrine and 
Galantamine 
Data are mean ± SD, n=3 (with exception of Aricept old group, n=2 due to outlier).  Y – Young, O – Old.  #p < 0.05, ### p <0.001 vs. 


































































































































































Figure 12. In vitro inhibition 
curves of Aricept, Tacrine and 
Galantamine on AChE and BChE 
in old and young rat plasma and 
brain.  Pooled rat plasma was 
used to perform a single assay.   
Three repeated assays were 
performed for brain AChE 
samples with a different young 
and old rat each time (n=3), 
points are mean ± SD.    









AChE BChE AChE 
Y O Y O Y O 
Aricept 14.2 18.1 - - 19.5 ± 6.6 22.1 ± 3.8 
Tacrine 140.6 153.5 100.8 102.9 162.8 ± 3.4 155.6 ± 13.2 
Galantamine - - - - 2627 ± 129 2597 ± 136 
 
Table 15. Changes in in vitro ChE inhibition represented by IC50 values of Aricept, Tacrine and Galantamine on AChE and 
BChE in plasma and brain from young and old rats 
Data for brain AChE IC50 are mean ± SD, n=3.  No means obtained for plasma AChE and BChE as pooled plasma samples were 
used.  Y – Young, O – Old.  Independent t-tests performed revealed no significant difference between young and old groups for brain 
AChE IC50. 
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4. 2. 3 Cholinergic-mediated behaviour in Tacrine-dosed rats 
To further investigate ageing changes in PD response of ChE inhibitors, a 
simple assessment of cholinergic-mediated behaviour (tremor, hypothermia, 
lacrimation and salivation) in response to Tacrine administration (PO, 10 mg/kg and 
30 mg/kg) was carried out in young and old rats.  The results are shown in figure 13 
with p-values of planned comparisons between all dose groups shown in table 16.   
Higher baseline cholinergic activities were observed on ageing, indicated by 
the presence of subtle tremor in limbs and consistent hypothermia in vehicle-dosed 
old rats throughout the experiment.  For all effects, response to Tacrine was 
significantly prolonged in the old rats compared to the young rats.  This is more 
striking at the 10 mg/kg dose level where responses in the young rats tended to 
recover to baseline levels by 6 h whereas old rats continue exhibiting cholinergic 
behaviour.  With regard to magnitude of response, salivation produced the most 
observable enhancement of effect with old rats producing almost three times the 
amount of saliva secreted in young rats at both dose levels (fig. 13d).  For tremor and 
hypothermia, the higher baseline cholinergic activity levels in the old rats may have 
contributed to a lower degree of response compared to the young rats as no dramatic 
enhancement in effect was seen like that of salivation.   
Interestingly, it was observed that upon dosing with Tacrine, tremor and 
hypothermia manifested more slowly in the old rats compared to the young.  This 
effect was more discernable at the 10 mg/kg dose level (see table 16, Young veh vs. 
Young 10 mg/kg and Old veh vs. Old 10 mg/kg for tremor and temperature).  
Increased salivation and lacrimation however, appeared more quickly in the old rats 
(fig. 13).   
 



































































































Figure 13. The 6 h time-course of acute cholinergic behavioural effects of Tacrine 
(PO dose at 10mg/kg and 30mg/kg) on (a) tremor, (b) rectal temperature, (c) 
lacrimation and (d) salivation in young and old LH rats.  Lacrimation scores of 
vehicle-dosed rats were zero and therefore not shown.  Data represented as mean and 
above SD bars (n=6, n=12 for vehicle groups).  The results were analysed in Statistica 
with ANOVA repeated measure test and planned comparisons were performed 
between groups (see Table 16). F values of ANOVA tests are as follows – tremor 
F(25, 210) = 13.68; lacrimation F(8, 60) = 2.2149; temperature F(25, 210) = 12.478; 
salivation F(25, 210) = 4.0989.   









Versus 0h 0.5h 1h 2h 4h 6h 
Young Veh 
Young 10mg/kg 1.000 0.447 0.004 <0.001 0.233 1.000 
Young 30mg/kg 1.000 <0.001 <0.001 <0.001 <0.001 <0.001 
Old Veh 0.009 0.024 0.126 0.099 0.071 0.091 
Old Veh 
Old 10mg/kg 0.655 0.256 0.209 0.017 0.009 0.165 
Old 30mg/kg 0.184 0.010 <0.001 <0.001 <0.001 <0.001 
Young 
10mg/kg 
Old 10mg/kg 0.024 0.053 0.661 1.000 0.012 0.019 
Young 
30mg/kg 












Versus 0h 0.5h 1h 2h 4h 6h 
Young 
30mg/kg 
Old 30mg/kg - 0.932 0.033 0.036 1.000 0.816 
Old 
10mg/kg 












Versus 0h 0.5h 1h 2h 4h 6h 
Young Veh 
Young 10mg/kg 0.400 <0.001 <0.001 <0.001 <0.001 0.239 
Young 30mg/kg 0.173 <0.001 <0.001 <0.001 <0.001 <0.001 
Old Veh <0.001 0.117 0.219 0.132 0.112 0.250 
Old Veh 
Old 10mg/kg 0.051 0.395 <0.001 <0.001 <0.001 0.005 
Old 30mg/kg 0.234 <0.001 <0.001 <0.001 <0.001 <0.001 
Young 
10mg/kg 
Old 10mg/kg 0.050 <0.001 0.059 0.346 0.140 0.023 
Young 
30mg/kg 













Versus 0h 0.5h 1h 2h 4h 6h 
Young Veh 
Young 10mg/kg 0.572 0.608 0.435 0.673 0.628 0.734 
Young 30mg/kg 0.098 0.179 0.071 0.424 0.462 0.432 
Old Veh 0.016 0.850 0.699 0.530 0.623 0.587 
Old Veh 
Old 10mg/kg 0.241 0.018 0.016 0.057 <0.001 0.016 
Old 30mg/kg 0.442 0.007 <0.001 <0.001 <0.001 <0.001 
Young 
10mg/kg 
Old 10mg/kg 0.025 0.075 0.083 0.083 0.003 0.028 
Young 
30mg/kg 
Old 30mg/kg <0.001 0.164 <0.001 <0.001 <0.001 <0.001 
 
Table 16. P-values of planned comparisons between groups to demonstrate age 
and treatment effects on acute cholinergic response in young and old LH rat.  
Red highlighted p-values indicative of statistical significance (p<0.05).  Statistical 
analysis for lacrimation results were limited to Young 30mg/kg, Old 10mg/kg and 
Old 30mg/kg groups for 0.5-6h only due to lack of variance in zero scores for the 
other groups and at the 0h timepoint.  
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4. 2. 4 Expression of muscarinic acetylcholine receptor subtypes in old and young 
LH rat brain 
Enhanced cholinergic responses may arise from an increase in muscarinic 
receptor-mediated response or decline in muscarinic receptor autoregulation of ACh 
release.  Muscarinic receptor expression in brain was determined for young and old 
rats by immunoblotting and results can be found in figure 14.  It was found that only 
muscarinic M2 receptor expression decreased significantly while M1, M3 and M4 
receptor subtypes showed no significant change in expression with age.  The 
expression of muscarinic M2 receptors in the old rats was decreased to a level 
approximately two thirds of that in the young. 
  66 
 
 


































Figure 14. Muscarinic receptor subtype expression in young and old LH rat brain.  (a) 
Representative western blots of M1-M4 receptor subtypes from four old and four 
young rats.  (b) Graphical representation of normalized expression.  Data represented 
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4. 2. 5 NMDA receptor expression in old and young LH rat brain and changes in  
binding affinity to Memantine with age 
Age-related alterations in expression of NMDA receptors in brain were 
studied to investigate potential changes in PD response to Memantine.  NMDA 
receptor expression was quantified and its binding affinity to Memantine was assessed 
in young and old rat brain membrane homogenate preparations.  From fig. 15a and b, 
a small but significant change in Bmax was observed with no significant change in KD.  
Actual values can be found in table 17.  The Scatchard analysis (fig. 15b) additionally 
revealed that single, high-affinity binding sites were present as opposed to two 
independent binding sites.  NMDA receptor expression is therefore inferred to 
decrease by about 15% on ageing in the LH rat. 
NMDA receptor binding affinity to Memantine as well as unlabelled MK-801 
was observed to be unchanged on ageing (fig. 15c, d) as demonstrated by a 
maintenance of Ki values for both compounds in young and old brain membranes 
(table 17). 
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Figure 15. (a) Saturation curves and (b) Scatchard transformation for specific binding 
of [
3
H]MK-801 to brain membrane preparations from young and old rats; Inhibition 
of [
3
H]MK-801 binding to young and old rat brain membrane preparations by (c) 
Memantine and (d) unlabelled MK-801.  Values are mean ± SD, n=5 (a), mean (b) 
and mean ± SD, n=3 (c, d).    ●    Young;      Old 
 
 Young Old 
Saturation binding 
KD (nM) 1.2 ± 0.2 1.1 ± 0.2 
Bmax (fmol/mg protein) 1716.2 ± 145.8 1455.2 ± 189.7* 
Competition binding 
Memantine Ki (nM) 320.2 ± 53.6 328.5 ± 52.0 
MK-801 Ki (nM) 1.9 ± 0.5 1.9 ± 0.5 
 
Table 17. Summary of parameters from [
3
H]MK-801 saturation binding and 
competition binding studies in young and old rat brain membranes in the 
presence of 10 μM glutamate and 10 μM L-glycine 
Values are mean ± SD, n=5 for saturation binding parameters and n=3 for competition 
binding parameters.  Independent t-tests indicate significant difference between young 
and old groups (*p < 0.05). 
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5 Discussion 
The aim of this work was to investigate the influence of age on PK and PD 
characteristics of gold standard AD drugs, Aricept, Tacrine, Galantamine and 
Memantine in the LH rat.  In addition, general alterations that may influence PK 
processes such as changes in CYP enzyme activity, P-gp transporter expression and 
renal and biliary excretory capacity were assessed.  The LH aged rats proved to be 
suitable for use in PK profiles as they recovered well from surgery and were similar to 
the young rats in terms of cannula patency duration.  However, handling limitations 
may exist due to their larger size.  The LH rat also showed an increased incidence of 
tumour formation upon ageing and rats with noticeable tumours were excluded in the 
study conducted.  Only two age groups (7 and 30 months) of animals were used here 
to establish an ageing effect but as general preclinical PK screening takes place in 3 
month old animals, the 7 month old group served as an intermediate age group.  
Conclusions drawn however are solely based on studied comparisons between 7 and 
30 month age groups since prior data from 2-3 month old animals showed similar 
results to those of 7 month old animals (see appendix).  Comparison of PK profile 
information obtained here with that from human studies would determine the 
translational potential of the aged LH rat model in predicting PK/PD changes with 
age.  In addition, use of the LH aged rat model would address the choice of rat strain 
in ageing studies and comparisons made with existing knowledge of age-related 
changes in the F344 rat would enable the risk of an over-reliance on a single strain to 
be assessed. 
5. 1 Physiological changes on ageing in the LH rat that influence PK of gold 
standard AD drugs in comparison with the F344 rat and humans 
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Although physiological changes on ageing which affect PK have been 
generally well-established, certain controversy remains with regard to phase I liver 
metabolism (Mc Lean and Le Couteur, 2004, ElDesoky, 2007).  The decline in CYP 
activity is consistently seen in rodent models, including the F344 rat (Warrington et 
al., 2003), and was replicated in this study with a decrease in CYP3A and CYP1A-
mediated in vitro metabolism.  However, this decline is not present in humans.  This 
has been attributed to the cumulative effects of genetics, lifestyle (diet, smoking, 
alcohol etc.), disease and co-administered drugs, which produce marked variability in 
CYP activities, masking age-related influences.  Constraints of study size and 
availability of human liver tissue also pose as contributing factors (Kinirons et al., 
2004, Schwartz, 2007).  Screening for drug metabolism changes on ageing would 
therefore be best established in vitro using liver microsomes from humans as opposed 
to rodents.  The decline in CYP activity in rats on ageing is proposed to arise from 
changes in growth hormone secretion where an age-related feminization in the male 
rat occurs with induction of female-specific CYP isoforms and concomitant loss of 
male-specific isoforms (Wauthier et al., 2007).  Although gender differences in CYP 
activity are also seen in humans, it is unclear if this feminization takes place on ageing 
(Schmucker, 2001, Wauthier et al., 2007).  The diminished CYP activity in old LH 
rats was the likely main cause for the trend of decreased clearance and increased 
extrapolated AUC seen across all treatment groups in the IV PK profiles.  This is 
supported by maintenance of urinary excretion with age in the LH rat in addition to 
minimally metabolized Memantine undergoing the lowest drop in clearance among all 
treatments (fig. 2). 
Maintenance of urinary excretion and reduced faecal excretion of marker 
compounds Memantine and Rosuvastatin seen in the old LH rat correlated with 
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previous findings of unchanged GFR and diminished bile flow and bile acid secretion 
rates in aged rats (Bengele et al., 1981, Goldstein et al., 1988, Handler et al., 1994).  
However, certain strains (mostly albino, e.g. Sprague Dawley, F344) were found to 
undergo renal changes on ageing which can give rise to marked drops in GFR at ages 
of 30 months and beyond (Goldstein et al., 1988).  This is due to the affliction of 
chronic progressive nephropathy (CPN), a rodent-specific disease characterized by 
degenerative renal morphological alterations increasing in severity with age, 
ultimately leading to glomerular atrophy and proteinuria.  Male rats are more greatly 
affected and low-protein or soy-based diets have been shown to attenuate disease 
progression (Goldstein et al., 1988).  As CPN is less a manifestation of ageing than a 
strain and sex-dependent disease (earliest indication of renal changes occurs at 3 
months of age in SD rats, Goldstein et al., 1988), its presence has to be taken into 
account when interpreting results in ageing studies which involve the F344 rat.  The 
LH aged rat model thereby offers an advantage in this respect.   
PK profiles of the gold standard AD drugs revealed that the volume of 
distribution varied bidirectionally upon ageing depending on drug type, increasing for 
Aricept and Memantine and decreasing for Galantamine.  This led to significant 
changes in initial drug concentrations in blood post-dose as well as elimination half-
life, potentially prolonging or shortening drug action.  In a clinical setting, these 
changes may substantiate the need for a loading dose adjustment.  Volume of 
distribution (Vd) can be influenced by drug factors such as partition coefficients 
(logP), ionization state, and affinity for various body tissues.  Physiological factors 
such as body composition (fat/water content), plasma protein levels and membrane 
transporters can also affect Vd (Cusack, 2004).  Galantamine has a calculated log P 
(clogP) of 1.02 while Aricept and Memantine have clogP values of 4.60 and 3.03 
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respectively.  Galantamine also has the highest polar surface area among all the drugs 
(from in-house database).  This gives rise to variations in tissue association where 
Aricept and Memantine would bind to fatty tissue compartments with greater affinity 
while Galantamine although still being lipophilic, may also associate with polar 
compartments to a greater extent than the other two drugs.  As body fat content 
increases with age while body water falls, contrasting directional movements of these 
drug levels in the blood and tissues may result.   
Other factors that affect Vd such as plasma protein binding and tissue binding, 
did not change to a great extent in the aged LH rat as observed from the in vitro 
brain:blood equilibrium dialysis assay (Results 4.1.4).  In aged F344 rats, Satterwhite 
et al. demonstrated a ~20% decrease in albumin levels giving rise to greater free 
fractions of NSAIDs ibuprofen (1991) and naproxen (1995) in plasma.   But as most 
NSAIDs are greater than 95% protein bound, the impact on free drug concentrations 
would be substantially greater compared to the less highly bound AD drugs.  The 
overall decline in plasma protein levels in the elderly however, is of minimal clinical 
significance and relevant changes arise mostly from age-associated diseases, 
malnutrition or post-operative states (McLean and Le Couteur, 2004, Cusack, 2004).   
In humans, a single ABCB1 gene encodes for the P-gp protein whereas in 
rodents, two closely located genes ABCB1a and ABCB1b are involved in its 
expression.   These genes share 90% homology with each other and 80% homology to 
the human form.  Consistent with prior findings, ABCB1a was expressed in the LH 
rat brain, liver, kidney and intestine while ABCB1b was found mostly in the brain 
(hippocampus) and liver (Wu et al., 2009).  ABCB1a, being expressed on the cerebral 
capillary endothelium, is said to have a greater role in the BBB than ABCB1b, which 
is expressed in brain parenchyma (Wu et al., 2009).  Ageing in the LH rat saw a 
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relatively unchanged ABCB1a mRNA expression overall except for an increase in the 
cerebellum.  ABCB1b on the other hand, saw a significant increase in expression 
across all tissues tested (greatest increase in liver and kidney) except for the 
hippocampus.  A study in F344 rat found that age-related changes in P-gp protein 
expression was tissue-specific with lymphocytic and hepatic P-gp expression 
increased with age, intestinal and BBB expression not significantly changed, and 
kidney expression showing a significant decline (Warrington et al., 2004).  The age-
related increase in ABCB1b liver expression in the LH rat correlated with the 
increased P-gp protein liver expression seen in F344 rats.  Increases in ABCB1b 
expression seen in other tissues however, may not be translated into higher protein 
levels due to ABCB1a being the main isoform expressed.  Although Warrington gave 
no reason for the age-related increased liver P-gp expression, it could be postulated 
that this may serve to extrude toxins which older organisms are more susceptible to or 
possess in accumulated amounts due to impaired renal or metabolic clearance.  An 
important point to note is the significant decline in kidney P-gp protein levels seen in 
aged F344 rats may be attributed to the presence of CPN (discussed earlier), where 
global renal atrophy may incur the loss of P-gp protein.  In LH rats which experience 
lower incidence of CPN, the main isoform in kidney ABCB1a had no significant 
change in expression although ABCB1b expression experienced a 6-fold increase.   
Interestingly, ABCB1b expression was considerably higher in the 
hippocampus than other brain regions.  A similar observation was made in adult male 
Sprague Dawley rats (Kwan et al., 2003).  This suggests that P-gp may afford a 
broader protection of the hippocampus due to its essential role in cognitive function, 
further supported by the maintenance of ABCB1a and 1b expression on ageing.  
Unlike human studies which found a decreased P-gp activity at the BBB (Bartels et 
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al., 2008, Toornliviet et al., 2006), there was no decline in expression of P-gp protein 
or main isoform ABCB1a mRNA in BBB of aged F344 and brain of LH rats 
respectively.  Maintenance of expression however does not necessarily indicate 
unchanged transport activity.  But the unaltered brain:blood ratios with age of the gold 
standard AD drugs, of which Aricept has some P-gp substrate specificity (Ishiwata etl 
al., 2007), indicates P-gp activity is likely maintained in LH rat.  In contrast, a 
significant increase in brain:plasma ratio of Aricept was seen in aged F344 rats 
although BBB permeability was previously shown to be unaltered in this strain 
(Kosasa et al., 1999, to be elaborated further in 5.2, Wadwahni et al., 1991).  BBB 
integrity changes with age may therefore vary between species and strain. 
In humans, PK studies investigating the effects of age found that only Aricept 
and Galantamine had a significantly different PK profile in the elderly (Table 3).  A 
prolonged half-life of Aricept attributed to a significantly larger volume of distribution 
rather than a decline in clearance was found in elderly patients (68-82 yrs) versus 
young adults (20-27 yrs).  Maximal Galantamine blood concentrations were 30-40% 
higher in older AD patients than healthy younger adults although there were no 
differences in AUC and half-life (Jaan et al., 2002).  The aged LH rat successfully 
predicted an increase in half-life of Aricept and Cmax value for Galantamine to similar 
degrees as those seen in humans, despite differences in CYP metabolism and P-gp 
activity (table 7).  Other physiological changes with age such as alterations in body fat 
and water composition that brought about similar changes in Vd of the gold standard 
AD drugs in humans and rats may therefore have a greater bearing in defining the 
overall PK profile of a drug in an aged condition.  This indicates that PK profiling in 
the aged LH rat could potentially be used as a predictive tool to establish PK effects 
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on ageing in humans.  However, further studies looking at more drug types would 
have to be performed to confirm the translational reliability of this model. 
5. 2 Physiological changes on ageing in the LH rat that influence PD response 
to gold standard AD drugs in comparison with the F344 rat and humans 
Ageing is characterized by a cognitive decline which has been closely linked 
to cholinergic hypofunction (Baxter et al., 1999).  Few studies have looked at how 
this hypofunction may affect the pharmacological response to cholinergic-interfering 
drugs in an aged system.  In this investigation, ChE-inhibiting AD drugs Aricept, 
Tacrine and Galantamine were administered to old and young LH rats and PD 
responses were assessed.  These include effects on AChE and BChE activity in brain 
and plasma, and induced cholinergic-mediated behaviours.   
On dosing with ChE-inhibiting drugs, an enhanced AChE and BChE 
inhibition was observed in plasma and brain of old compared to young LH rats.  
However, similar drug concentrations when applied in vitro induced the same extent 
of AChE and BChE inhibition as shown by the maintenance of IC50 values.  This was 
despite the fact that ChE activity levels were altered in the aged rats, with 
significantly increased plasma ChE activity and a trend towards a decrease in brain 
ChE activity.  Greater concentrations of drug reaching target tissues would likely 
explain the increased ChE inhibition in dosed old rats.  Accordingly, PK data from the 
same animals revealed a trend of increased concentrations of drug in blood and brain 
although only the increase in Aricept brain concentrations was significant.  A similar 
study by Kosasa et al. (1999) found that aged F344 rats also experienced more potent 
ChE-inhibiting effects of Aricept and Tacrine on brain and peripheral tissues.  In 
addition, they experienced the same directional alterations in baseline ChE activity, 
increasing in plasma and decreasing in brain.  In contrast however, PK/PD effects 
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were amplified in the F344 rats.  Drug levels in brain and plasma were significantly 
higher by ~2-4 times in 26 mth compared to 2 mth old rats accompanied by increased 
brain:plasma ratios, leading Kosasa to similarly attribute the enhanced ChE inhibition 
to PK.  We measured Aricept and Tacrine levels in 2 mth old LH rats and similar 
results were obtained with that of 7 mth old rats (i.e. < 2 times increase in drug levels 
with age, see appendix).  Accordingly, the extent of ChE inhibition was significantly 
greater in the F344 rats with 2.5 mg/kg of Aricept inhibiting total ChE in brain to 30% 
of control in aged F344 rat compared to 3 mg/kg of Aricept exerting inhibition of only 
up to 90% of control in aged LH rats.  This hints at a potentially more substantial 
PK/PD change with age in F344 rats compared with LH rats. 
Kosasa only looked at total ChE activity in F344 rats, but a study by Sastry et 
al. (1983) reported an upregulated BChE activity in brain of aged F344 rats instead of 
a decline.  BChE, also referred to as pseudocholinesterase or non-specific 
cholinesterase, has recently shown to have an important role in normal cholinergic 
function and development of AD through its contribution to ACh hydrolysis (Darvesh 
et al., 2003).  Its circulating form is produced in the liver but it is also synthesized in 
the brain, where it is localized to glial cells and capillary endothelium, with some 
association to neurons in specific nuclei (Ballard et al., 2005).  The observation of 
upregulated BChE activity in brain with age would correspond with classical 
morphological data of an increased glial/neuron ratio on ageing (Meneguz et al., 
1992).   However, Sprague Dawley rats were also found to experience similar brain 
BChE activity reduction on ageing (Meneguz et al., 1992).  Meneguz also noted that 
F344 rats had an accelerated ageing response in terms of other cholinergic changes 
(ChAT, muscarinic receptor density) compared with other rat strains in his lab, an 
observation not isolated to him alone (Michalek et al. 1989).  The enhanced ageing in 
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F344 rats was seen in this study as well from the increased PK and PD sensitivity to 
gold standard AD drugs.  BChE activity in human cerebrospinal fluid was found to be 
maintained with age (Atack et al., 1988) but it is upregulated in human AD brains 
(Darvesh et al., 2003, Ballard et al., 2005).  Consequently, there lies a potential for 
ageing responses to be more pronounced in the F344 rat strain leading to 
overestimation of normal ageing changes in humans. 
Cholinergic behaviour assessment in young and old LH rats picked up: 1) a 
trend of increased baseline cholinergic responses in vehicle-dosed old rats with 
consistent hypothermia and presence of subtle limb tremor.  2) Enhanced 
peripherally-mediated cholinergic behaviour (salivation, lacrimation) and less 
sensitive centrally-mediated cholinergic behaviour (tremor, hypothermia) in terms of 
response time and magnitude of effect during the initial 2 h post-dose with Tacrine in 
the old rats.  3) Prolonged cholinergic response to Tacrine in the old rats compared 
with the young rats. 
The induced cholinergic responses are a result of an over-stimulation of 
muscarinic ACh receptors (mAChRs) by the excessive ACh produced from Tacrine 
inhibition of the ChEs.  The mAChRs belong to a superfamily of plasma membrane 
bound G-protein coupled receptors which mediate a range of physiological functions 
in the parasympathetic nervous system including the contraction of smooth muscle, 
stimulation of glandular secretion, and reduction in heart rate (Gomeza et al., 1999).  
They have also been implicated in learning and memory processes and may contribute 
to cognitive symptoms in AD (Tayebati et al., 2002).  Five receptor subtypes have 
been cloned and sequenced (M1-M5) and the generation of knockout (KO) mice has 
enabled the individual roles of each mAChR subtype to be clearly evaluated.  A 
summary of effects from deletion of each mAChR subtype can be found in table 18.  
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From here, the M2 mAChR subtype can be inferred to have a critical role in 
mediating fine whole body tremors and hypothermia due to the absence or dramatic 
decrease in these responses in the M2 KO mice.  Similarly, salivation is 
predominantly mediated by the M3 mAChR with some involvement of the M1 and 
M4 mAChRs.  Lacrimation response was not noted in the mAChR KO mice but it is 
likely mediated by M3 mAChRs as they are found extensively in the eye (Bymaster et 
al., 2003).   
It may be postulated that varying concentrations of Tacrine in blood and brain 
of old rats accounted for observation 2 and 3.  Differences in blood and brain Tacrine 
concentrations at 1 h post-dose between old and young rats however, were not 
significantly altered with no trend towards lower brain concentrations to explain the 
diminished central cholinergic effects.  Similarly, the 6 h PO PK profile showed 
Tacrine blood concentrations in old rats returning to similar baseline levels as young 
rats despite significantly higher concentrations at 1.5 and 2 h (fig. 3).  This excludes 
the effect of PK on the potentiated cholinergic response seen in old rats.  However, it 
cannot be ruled out that the higher dose used in cholinergic behaviour studies (10 and 
30 mg/kg as opposed to 3 mg/kg for PK study) may have overwhelmed drug 
clearance systems in the old rat leading to greater accumulation of Tacrine in the 
bloodstream.  On the other hand, Pedigo et al. (1984) observed that 
intracerebroventricular injection of oxotremorine (muscarinic agonist) also produced 
an age-related hypothermic sensitivity, suggesting other mechanisms may be 
involved. 
Immunoblotting of the M1-M4 mAChR subtypes in old and young LH brains 
revealed that only the M2 mAChR subtype underwent a significant decline in protein 
expression on ageing.  The slower manifestation and reduced magnitude of 
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hypothermic and tremor responses could therefore have arisen from a corresponding 
decrease in M2 mAChR stimulation in the old rats.  Autoradiographic studies of the 
aged F344 rat hippocampus also showed a consistent decrease in M2 mAChR binding 
accompanied by less regular changes in M1, M3 and M5 binding (Tayebati et al., 
2002).  And an overall decline in muscarinic binding has been replicated across 
several studies with different strains of rats (Araujo et al., 1990, Vannucchi et al., 
1997, Karanth et al., 2007, Pedigo et al., 1984).  Only a few studies have 
characterized cholinergic behaviour on muscarinic stimulation.  Pedigo found that 27 
mth old F344 rats underwent a delayed onset of hypothermia but experienced a 
greater drop in temperature compared to 3 and 9 mth old rats when dosed with 
muscarinic agonist, oxotremorine.  Baseline body temperatures showed no age-related 
differences.  A study in 8 and 34 mth Wistar rats found decreased baseline 
temperatures and a similar longer latency to reach maximal hypothermia in the old 
rats in response to oxotremorine (Martin et al., 1985).  The mechanisms by which M2 
mAChR brings about tremor symptoms remain unknown but hypothermic effects are 
thought to be mediated by mAChRs in thermoregulatory centres of the hypothalamus 
(Gomeza et al., 1999).  The delayed onset of hypothermia with age seen across rat 
strains may therefore be due to a downregulation of the M2 mAChRs in these 
thermoregulatory centres. 
Unlike the M1, M3 and M5 mAChRs which are coupled with the Gαq/11 
family that promotes stimulatory activity and promotes neurotransmitter release, the 
M2 and M4 mAChRs are coupled to Gαi/o activation which mediates inhibition of 
voltage-gated calcium channels, thereby acting as autoreceptors inhibiting ACh 
release (Bymaster et al., 2003).  From M2-M4 single and double KO mice, M2 
mAChR was found to regulate release of ACh in the cortex and hippocampus and M4 
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mAChR in the striatum.  The loss of both receptors led to a complete abolishment of 
oxotremorine-induced inhibition of potassium-stimulated ACh release (Bymaster et 
al., 2003).  The downregulation of M2 mAChRs in the old rat LH brain could 
therefore reduce the autoinhibitory effect on ACh release, prolonging central 
cholinergic responses in the old rat.  In vitro studies of potassium-stimulated ACh 
release saw an attenuated effect of M2-antagonist (AF-DX 116) on inducing ACh 
release in hippocampal and cortical slices of aged (27 mth) Long Evans rat, compared 
to 3 and 9 mth rats (Araujo et al., 1990).  Likewise, the reduction of ACh release from 
mAChR stimulation by excessive ACh produced by application of ChE inhibitor, 
eserine, was lessened on ageing (Buyukuysal et al., 1998).  However in opposition to 
these findings, a study which looked at in vivo ACh release from microdialysates from 
cortex and hippocampus have found an age-related enhancement of ACh release 
instead upon application of M2 antagonist (Vanucchi et al., 1997).  More studies are 
therefore necessary to establish a significant trend of reduced M2 mAChR 
autoregulatory response with age. 
This decreased ACh autoregulation from M2 mAChR downregulation could 
also explain the presence of baseline central cholinergic behaviors and enhanced 
peripherally-mediated cholinergic responses in old rats.  However, M2 KO mice 
showed no spontaneous locomotor activity and oxotremorine-induced salivation 
remained largely unaffected.  Studies have found increased expression and binding 
affinity of mAChRs in the salivary glands of aged rats, but an uncoupling of receptors 
to intracellular Ca2+ signals in acinar cells also took place.  These effects on 
salivation response however, were not assessed (Seagrave et al., 1996).   
A decrease in homeostatic reserve accompanies ageing and impairments in 
baroreflex, thermoregulation, vascular stability and cognitive reserve are known to 
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take place.  These result in an increased incidence of syncope, falls, hip fractures, 
hypothermia, stroke, and dementia in the elderly (Lotrich and Pollock, 2005).  
Therefore, although detailed mechanisms are yet to be elucidated this decline in 
homeostatic mechanisms likely contributes to the protracted return back to 
equilibrium in the old rats following pharmacological challenge.  Similarly, the 
presence of basal cholinergic symptoms in the old rats may result from impaired 
homeostatic mechanisms which function to maintain a normal body temperature and 
muscle tone.  
There have been numerous reports on a decrease in NMDA receptor 
(NMDAR) expression on ageing (Mitchell et al., 1998) but as some strain-dependent 
reductions of NMDAR binding have been observed in aged mouse brain (Peterson 
and Cotman, 1989), NMDAR binding with [
3
H]MK-801 was evaluated in LH old and 
young rat brains.  Potential ageing effects on PD response of Memantine was also 
explored for the first time in terms of binding affinity to NMDA via competition 
binding assays.  The experiments revealed a slight decrease in total NMDA receptor 
density with no change in binding affinity to Memantine as well as MK-801 with age.  
This does not reflect changes in PD response however as functional activity of the 
NMDA receptors was not assessed.  The extent of decline in NMDA total receptor 
binding was similar to that of F344 rats and ranged from about 10-20% with similar 
maintenance of KD for MK-801 (Mitchell et al., 1998, Tamaru et al., 1991).  In 
addition, [
3
H]MK-801 binding to human frontal cortex was also found to decrease 
with age (Piggott et al., 1992).  PD response of NMDA receptors on ageing was found 
to be attenuated based on experiments that detected a decrease in NMDA-stimulated 
release of neurotransmitters in hippocampal, cortical and striatal slices with age 
(Gonzales et al., 1991).  Conversely, neurons acutely dissociated from frontal cortices 
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of old mice had an increased response to ifenprodil (NMDAR antagonist) compared 
to young mice (Kuehl-Kovarik et al., 2003).  Future investigations on NMDAR 
functional changes with age and their impact on PD response to Memantine are 
therefore required. 
5.3 Relevance and application of findings  
This project has provided a general but comprehensive overview on the PK 
and PD alterations that may occur with age using the gold standard AD drugs in the 
LH rat (Table 19).  The aged LH rats used in this study were found to undergo similar 
age-related PK profile changes of gold standard AD drugs with that in humans.  
Although further testing with drugs of a varying range of PK properties would be 
required to ascertain its use as a predictive tool, its application into the drug screening 
cascade is limited by the significant resources needed to maintain aged animals and 
perform in vivo PK profiling.  Nevertheless, it can be applied to explore ageing PK 
changes of drug candidates with a narrow therapeutic range targeted for the elderly 
population.  This may help in the estimation of appropriate dose levels for entering 
clinical trials, avoiding potential toxicity issues and also ensuring an appropriate level 
of drug efficacy is achieved in the elderly.   
PD sensitivity was enhanced in the aged LH rats with respect to ChE 
inhibiting AD drugs and this was related not only to accompanying PK changes but 
also to modifications in target receptor expression.  The M2 mAChR subtype in 
particular showed an age-related decline which may potentially have resulted in the 
altered cholinergic response to Tacrine seen in the old rats.  As M2 mAChR 
expression is also decreased in the cerebral cortex of AD patients (Mash et al., 1985), 
potential alterations in PD response to ChEIs may occur in an AD setting.  It may be 
postulated that the decreased expression of M2 mAChR in AD could limit its 
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autoregulatory control on presynaptic ACh release, increasing ACh release and 
enhancing the PD response of ChEIs.  However due to a lack of studies examining the 
effects of ChEIs on normal versus AD models in humans or rodents, this association 
has not been established. 
 Ageing was not found to significantly alter drug-target interaction as 
illustrated by the unchanged binding affinity of Memantine to the NMDAR in 
addition to the observation that similar concentrations of externally applied ChE 
inhibitor was able to bring about the same extent of ChE inhibition in old and young 
tissues.  Instead, ageing changes in PD responses are likely derived from alterations 
relating to the target tissue.  This is regulated by the number of target molecules the 
tissue expresses and the signalling interactions within or with neighbouring structures 
which are involved in homeostatic pathways that serve to restore equilibrium towards 
its inactivated state.  Further evaluation of these homeostatic pathways to identify the 
signalling players involved would be helpful for drug development.  Reason being the 
development of strategies to regulate their activity could serve to reduce the adverse 
pharmacological reactions common in the elderly or alternatively prolong receptor 
activation state to extend the drug’s pharmacological action.  Moreover, knowledge of 
receptor expression changes with age would enable improvements in drug targeting 
for age-related diseases.  
The project has also highlighted potential issues in the use of the F344 rat as 
an ageing model.  This includes the presence of CPN in the aged F344 rat that occurs 
at virtually 100% incidence by 2 years of age and involves a spectrum of renal 
alterations which differ from those seen in the ageing human kidney (Hard and Khan, 
2004).  It not only exerts PK effects by reducing renal elimination but can also 
adversely impact carcinogenicity studies as rats with CPN have a higher incidence of 
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renal tumour formation, resulting in an exaggerated hazard assessment of potential 
drugs (Hard and Khan, 2004).  Greater PK/PD changes with age were demonstrated in 
aged F344 rats by the comparative ChE inhibition study by Kosasa et al. (1999).  This 
revealed significantly greater ChE inhibition and higher blood and brain 
concentrations of Aricept and Tacrine compared to the LH rat at similar dose levels.  
In addition, the F344 rats were also noted to undergo an accelerated ageing compared 
with other strains of the same age as indicated by a greater decline in cholinergic 
markers.  The extensive use of a single rat strain to demonstrate ageing changes is a 
drawback in itself and the accelerated ageing responses in the F344 rats further 
substantiate the need to include other strains in ageing studies to avoid 
overestimations when translating these changes to humans.  Outbred strains like the 
LH rat however have the tendency to become obese with age, posing handling 
difficulties and higher drug amounts required.  Nevertheless, the combinatorial use of 
several rat strains to establish ageing trends would bolster confidence when 
translating results into humans.   
Applications of ageing research are wide-ranging and understanding ageing 
mechanisms not only allows for better prediction of an aged pharmacological 
response, but clarifies pathways involved in age-related diseases enabling the 
formulation of interventions to stop or reverse disease progression.   Parallel to this, 
numerous research groups are focussing on understanding the ageing process in an 
effort towards finding ways to extend the average lifespan.  With the ever-growing 
ageing population, the relevance of ageing research would only increase, calling for 
even more intensive research efforts. 
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Muscarinic receptor subtype 
Measurement M1 M2 M3 M4 M5 
Parasympathetic effects 












































Central Nervous system effects 
PI hydrolysis in hippocampus 
MAPK stimulation 
Blockade of dopamine release 
Autoreceptor function 
Cerebral vasculature tone 
Hyperlocomotion 
Blockade of dopamine-agonist 
induced hyperactivity 











































































Note: N, normal function or no effect; ↓ indicates reduced activity; ↑ indicates 
increased activity; absent indicates loss of function; number of arrows indicate 
magnitude of effect, - equals not tested; + indicates a positive effect. 
 
(Bymaster et al., 2003) 
 





 LH rat F344 rat Human 
Changes on ageing that affect pharmacokinetics 
CYP metabolism ↓ ↓ ↔ 
Urinary excretion  ↔   ↓  ↓ 
Biliary excretion  ↓  ↓  Unestablished 
Volume of distribution Dependent on drug lipophilicity Dependent on drug lipophilicity Dependent on drug lipophilicity 
P-gp (ABCB1) 
expression/activity 









Brain permeability ↔ Possible ↑  Possible ↑ 
Changes on ageing that affect pharmacodynamics 
ChE inhibition ↑ due to PK ↑↑ due to PK Unestablished 
ChE inhibitor-induced 
cholinergic behaviour 
↑ not only due to PK Unestablished Unestablished 
M2 mAChR expression ↓ ↓ Unestablished 
NMDAR binding ↓ ↓ Unestablished 
Table 19. Summary of main findings in comparison with F344 rat and human
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6 Conclusion 
In summary, physiological changes found to affect PK of the gold Standard 
AD drugs in the aged LH rat involved a decline in CYP3A and CYP1A activity which 
led to a trend of reduced clearance for all drugs.  This decline however did not lead to 
significant changes in total drug exposure, indicated by unchanged AUC values.  
Ageing changes in P-gp mRNA expression did not substantially impact brain 
permeability of drugs.  Overall alterations of PK parameters from the aged LH rat 
however, correlated well with those seen in aged humans.  This indicates its potential 
use in predicting PK alterations in the elderly especially for drugs targeted towards 
the elderly population with a narrow therapeutic range. 
Enhancement of PD sensitivity in the aged LH rat was derived not only from a 
decline in PK elimination of a drug but also from target receptor expression changes 
with age.  Expression of M2 mAChR was found to decline on ageing which was 
proposed to give rise to increased latency in tremor and hyopthermia manifestation.  
Its autoregulatory effect on ACh release was also suggested to be reduced, bringing 
about a prolongation of cholinergic response in the old rats on Tacrine dosing.  
Impairments in homeostatic reserve were also postulated to play a role.   
Results from the LH rat suggested that ageing changes were more intense in 
the F344 rat.  They were found to undergo greater PK effects as well as PD changes 
on ageing as indicated by prior studies.  This necessitates the use of several strains of 
rat to establish a normal ageing response in humans.   
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The following data compare PK results from 2-3 month old LH rats with the age groups used in the project (i.e. 7 and 30 month).  Blood and 
brain concentrations of Aricept and Tacrine following PO dosing showed no statistical distinction between 2 month and young (7 month) group.  
PO PK profiles of Aricept previously done in 3 month old LH rats were also were not statistically different to young group at any time-point. 
 
Drugs 
Blood Concentration (µM) Corrected Brain Concentration (µM) Brain:Blood 
2 month Young Old 2 month Young Old 2 month Young Old 
Aricept 0.08 ± 0.02 0.13 ± 0.01 0.21 ± 0.11# 0.40 ± 0.08 0.57 ± 0.09 1.02 ± 0.23* 4.98:1 ± 0.22 4.40:1 ± 0.27 5.30:1 ± 1.83 
Tacrine 0.11 ± 0.05 0.11 ± 0.03 0.19 ± 0.12 1.09 ± 0.46 1.23 ± 0.30 1.72 ± 0.93 10:07:1 ± 0.77 11.03:1 ± 1.17 9.46:1 ± 0.71 
Table 20. Blood, brain concentrations and brain:blood ratio values of Aricept and Tacrine in 2 month old, young (7 month old) and old 
(30 month old) LH rats 1h after PO administration at 3mg/kg 
Values are mean ± SD. Corrected brain concentration refers to measured brain concentration minus vascular volume of blood present in brain which is estimated to be 1.5% 
of blood concentration. One-way ANOVA followed by planned comparisons between groups show significance at #-2 month vs. old group (p < 0.05) and *-2 month and 
young vs. old group (p < 0.01 and p< 0.05 respectively).  
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Figure 16.  Concentration-time profiles of Aricept in 3 month old, young (7 month) and 
old (30 month) LH rats dosed orally (3mg/kg, 5ml/kg).  Points represent mean ± SD, 
n=3 except old group, n = 5.  Repeated measure ANOVA was performed and planned 
comparisons among groups reported significance (p < 0.05) at certain time-points: #-3 
month vs. old group; *-young vs. old group.        
  ▲  3 month;   ●   Young;    Old       
 
